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ABSTRACT (English) 
Neuronal differentiation is a complex process characterized by different cellular events. It is finely 
regulated by numerous transcription factors, many of which have been identified while others 
remain unknown. Recently, long non-coding RNAs (lncRNAs) have emerged as key regulators 
of gene expression, with an essential role in cell differentiation. Therefore, the identification and 
characterization of these transcripts and the functional relationships between mRNA and lncRNA 
are fundamental to the understanding the complex transcriptional processes underlying gene 
regulation. In this regard, an essential molecule for neuronal development, the neurotrophin 
BDNF (Brain-Derived Neurotrophic Factor), is known for its action in post-transcriptional 
regulation, while little is known about the transcriptional programs it triggers and through which 
it influences the development and survival of neurons. The results presented in this thesis concerns 
the identification of several Immediate Early Genes (IEGs), belonging to both coding and non-
coding that, engaged by BDNF, can play a fundamental role in the biology of this neurotrophin. 
Among coding genes, the involvement of the transcription factor EGR1 (Early growth response 
protein 1) in neuronal differentiation was investigated. Taking advantage of genome editing 
techniques (CRISPR-Cas9) and the SH-SY5Y cell line as a human neuronal model, I showed that 
the knockout cells for EGR1 are unable to differentiate, underlining an essential role of the 
transcriptional programs regulated by EGR1 in the survival of neurons. Furthermore, I identified 
a new alternative splicing isoform for EGR1 likely involved in neuronal differentiation. The 
preliminary results suggested that this isoform may act as a dominant negative of the canonical 
isoform, contributing to a fine regulation of its effect on transcriptional regulation. In the final 
part of my thesis, I focused my efforts on a primary characterization of the most differentially 
expressed lncRNA under BFNF stimulation, the LINC00473 gene. I provided evidence that this 
gene may encode for a little protein highly conserved in primate species. Functional analysis by 
the use of a KO cell line generated by CRISPR/Cas9 showed that the putative protein affected the 
transcript level of the IEGs with a relevant impact on the regulation of gene expression. 
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ABSTRACT (Italian) 
Il differenziamento neuronale è un processo complesso caratterizzato da diversi eventi cellulari. 
È finemente regolato da numerosi fattori trascrizionali, molti dei quali sono stati identificati, 
mentre altri restano ancora sconosciuti. Recentemente, i long non-coding RNAs (lncRNAs) sono 
emersi come regolatori chiave dell’espressione genica, con un ruolo essenziale nel 
differenziamento cellulare. Pertanto, l’identificazione e la caratterizzazione di tali trascritti e delle 
relazioni funzionali tra mRNA e lncRNA, risultano fondamentali per la comprensione dei 
complessi processi trascrizionali alla base della regolazione genica. A tal proposito, una molecola 
essenziale per lo sviluppo neuronale, la neurotrofina BDNF (Brain-Derived Neurotrophic Factor) 
è nota per la sua azione mediante la regolazione post-trascrizionale, mentre poco si conosce sui 
programmi trascrizionali che innesca e tramite i quali influenza lo sviluppo e la sopravvivenza 
dei neuroni. Il presente lavoro di tesi ha permesso di individuare una serie di Immediate Early 
Genes (IEGs), sia codificanti che non codificanti, che, ingaggiati da BDNF, possono avere un 
ruolo fondamentale nella biologia di tale neurotrofina. Tra i codificanti, l’attenzione si è 
focalizzata sul fattore di trascrizione EGR1 (Early growth response protein 1), il cui ruolo è 
particolarmente documentato nell’adulto. Grazie alle tecniche di genome editing basate sul 
CRISPR-Cas9 ed alla linea cellulare SH-SY5Y, è stato possibile dimostrare una funzione chiave 
di EGR1 nello sviluppo dei neuroni. Le cellule knockout per tale fattore di trascrizione sono infatti 
risultate incapaci di differenziare, sottolineando un’importante influenza dei programmi 
trascrizionali regolati da EGR1 nella sopravvivenza dei neuroni. Inoltre, gli studi riportati nel 
presente lavoro di tesi hanno permesso di identificare un’isoforma di splicing alternativo inedita 
per EGR1. I risultati preliminari ottenuti fanno ipotizzare che tale isoforma possa agire come 
dominante negativo dell’isoforma canonica concorrendo ad una fine regolazione della funzione 
di EGR1. Un altro gene su cui il presente lavoro di tesi si è concentrato è invece appartenente a 
quelli codificanti per i lncRNA, noto come LINC00473. Le analisi hanno permesso di ipotizzare 
che tale gene possa avere una rilevante funzione nello sviluppo e funzionamento dei neuroni. In 
particolare, è stato interessante osservare che probabilmente tale gene codifica per una piccola 
proteina primate-specifica il cui ruolo può influenzare l’espressione di altri IEGs con un impatto 
rilevante sulla regolazione dell’espressione genica. 
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ABBREVIATIONS 
 
AD  Alzheimer disease 
AKT  Serine-Threonine Protein Kinase 
APAF-1  Apoptotic Peptidase Activating Factor 1  
ARC  Activity Regulated Cytoskeleton Associated Protein 
ATF3  Activating Transcription Factor 3 
BACE1  Beta-secretase 1 
BACE1-AS Beta-secretase 1 Antisense 
BAX  BCL2 Associated X, Apoptosis Regulator 
BCL-2  B-cell lymphoma 2 
BDNF  Brain-derived neurotrophic factor 
BID  BH3 Interacting Domain Death Agonist 
BSA  bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
ceRNA  Competitive endogenous RNA 
C-FOS  Fos Proto-Oncogene C 
CLIP  cross-linking immunoprecipitation 
CNS  Central Nervous System 
CPAT  Coding Potential Assessment Tool 
CRISPR/Cas9 Clustered Regularly Interspaced Short Palindromic Repeats 
CYP26a1  Cytochrome P450 Family 26 Subfamily A Member 1 
DAPI  4′, 6-diamidino-2-phenylindole 
DAVID  Functional Annotation Bioinformatics Microarray Analysis 
DIABLO  Diablo IAP-Binding Mitochondrial Protein 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide 
DTT  Dithiothreitol 
DUSP5  Dual Specificity Phosphatase 5 
ECL  Enhanced ChemiLuminescence 
EDTA  ethylendiaminetetracetic acid 
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EGR1  Early Growth Response 1 
EGR2  Early Growth Response 2 
EGR3  Early Growth Response 3 
EGR4  Early Growth Response 4 
EGTA  Ethylene Glycol Tetraacetic Acid 
EMT  Epithelial-mesenchymal transition 
EP2  E-type prostanoid receptor 2 
EP4  E-type prostanoid receptor 4 
ERK  Extracellular signal–regulated kinase 
F3  Coagulation Factor III, Tissue Factor 
FAM46A Terminal Nucleotidyltransferase 5A 
FBS  Fetal Bovine Serum 
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GDNF  Glial Cell Derived Neurotrophic Factor 
GREAT  Genomic Regions Enrichment of Annotations Tool 
GO  Gene ontology 
gDNA  genomic DNA 
gRNA  RNA guide 
HAND2-AS Heart And Neural Crest Derivatives Expressed 2 Antisense 
HD  Huntington disease 
H1FX  H1 Histone Family Member X 
HOMER1a Homer Scaffold Protein 1a 
HOXD  Homeobox D 
HPRT1  Hypoxanthine Phosphoribosyl Transferase 1 
IAPs  Apoptosis inhibitors 
IEG  Immediate-early gene 
IGF2BP1 Insulin Like Growth Factor 2 MRNA Binding Protein 1 
IGF2BP2 Insulin Like Growth Factor 2 MRNA Binding Protein 2 
IGF2BP3 Insulin Like Growth Factor 2 MRNA Binding Protein 3 
IGFBP7  Insulin Like Growth Factor Binding Protein 7 
INDEL  INsertion/DELetion 
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iPSCs  Induced pluripotent stem cells 
KCl  potassium chloride 
KLF10  Kruppel Like Factor 10 
KO  knockout 
lncRNA  long non-coding RNA 
lncRNome long noncoding RNA knowledgebase 
LTD  long-term depression 
LTP  Long term potentiation 
MALAT1 Metastasis Associated Lung Adenocarcinoma Transcript 1 
MAPK  Mitogen-activated protein kinase 
MAP3K14 Mitogen-Activated Protein Kinase Kinase Kinase 14 
MgCl2  magnesium chloride 
MIAT  Myocardial infarction associated transcript 
miRNA  microRNA 
NaCl  sodium chloride 
ncRNA  non-coding RNA 
NEUROD1 Neuronal Differentiation 1 
NGF  Nerve growth factor 
NGFR  Nerve growth factor receptor 
NPAS4  Neuronal PAS Domain Protein 4 
NR4A1  Nuclear Receptor Subfamily 4 Group A Member 1 
NR4A3  Nuclear Receptor Subfamily 4 Group A Member 3 
NRAGE  Neurotrophin receptor-interacting MAGE homologue 
NRIF  Neurotrophin receptor interacting factor 
NT-3  Neurotrophin-3 
NT-4  Neurotrophin-4 
NTRK  Neurotrophic tropomyosin receptor kinase 
PCD  Programmed cell death    
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PCR  Polymerase Chain Reaction 
PD  Parkinson disease 
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PKA  Protein kinase A 
PKC  Protein kinase C 
PLC  Phospholipase C 
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PUM2  Pumilio RNA Binding Family Member 2 
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RHOB  Ras Homolog Family Member B 
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SC-1  SPARC-like protein 1 
SDS  Sodium Dodecyl Sulphate 
SEM  mean standard error 
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SIK1  Salt Inducible Kinase 1 
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1. INTRODUCTION 
1.1 Human Neurodevelopment 
The CNS is probably the most complex of all the biological systems. The mature brain is made 
up of over 100 billion neurons that represent the information processing cells that can vary in their 
size, shape and function (Pakkenberg and Gundersen, 1997). Basically, neurons have a cell body 
(called the soma) and various processes that include dendrites, branching processes that extend 
only for a short distance away from the neuron cell body, and an axon, a separate process that is 
typically longer than the dendrites (Figure 1). To support the general function of the nervous 
system, neurons have evolved special abilities for sending electrical signals along axons. These 
are wrapped in a fatty substance called myelin that makes the transmission of electrochemical 
signals between regions efficient (Figure 1; Stiles and Jernigan, 2010). The communication 
between neurons is achieved at synapses by the process of neurotransmission.  
 
Fig 1. Schematic drawing of a neuron (Stiles and Jernigan, 2010). 
 
During embryogenesis and adulthood, the development of nervous system is a complex and 
dynamic process that involves a precisely orchestrated sequence of genetic, epigenetic, 
environmental, biochemical and physical events. The differentiation of neural progenitor cells 
that will form nervous system requires complex cascades of molecular signals and the fine 
regulation of gene expression networks. Neural progenitors are self-renewing cells able to divide 
and increase their number. During embryogenesis, after several replication cycles, the number of 
cells increases until the cell division switches from symmetric to asymmetric. In this new phase, 
two different types of cells are produced: a neural progenitor cell, which continues to proliferate 
(self-renewal), and a neuron, which no longer proliferates. In the early stages of development, 
neurons undergo to a migration process referred to as somal translocation (Figure 2 A) (Nadarajah 
and Parnavelas, 2002; Stiles and Jernigan, 2010). As development proceeds, the brain becomes 
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larger and the primary mode of neuronal migration changes. Because of the greater distances, 
neurons require a special population of cells called “radial glial guides” to support their migration 
(Figure 2 B) (Rakic, 1972; Stiles and Jernigan, 2010). Although the radial glial guides were 
originally thought to be a special, transient population of cells, it has recently been discovered 
that they are neural progenitor cells (Noctor et al. 2001; Noctor et al. 2002; Parnavelas et al. 2002; 
Weissman et al. 2003; Stiles and Jernigan, 2010). Very recent studies have identified a second 
proliferative zone that will later develop into the basal ganglia. These neurons traverse long 
distances using a mode of migration that has been termed “tangential migration” (Figure 2 C). 
Tangential migration involves a variety of signalling pathways not seen in radial migration (Marin 
and Rubenstein 2001; Huang, 2009; Stiles and Jernigan, 2010; Valiente and Marin 2010). 
 
Fig 2. Different modes of neuronal migration. (A) Neuron migration by somal translocation: neuron 
extends a long basal process, which is an extension of the cell body and attaches itself to the pial surface, 
the outer surface of the developing brain. The nuclei of cells then move through the cytoplasm of the basal 
process. (B) Neuron migration radial glial guide: guides extend a basal process that attaches to the pial 
surface of the brain which forms a kind of scaffold along which neurons can migrate. Each glial scaffold 
can support the migration of many neurons. (C) Neuron migration from the second proliferative zone in 
ganglionic eminences by tangential migration (arrows indicate the direction of migration for different 
neuron populations). Neurons use several guidance molecules produced in local regions along their 
migratory route to direct their movement into the cortex. (Stiles and Jernigan, 2010). 
 
The migration of neurons into the developing neocortex leads to the formation of an ordered 6-
layer structure (Cooper, 2008; Stiles and Jernigan, 2010). At this point, young neurons must 
become part of information processing networks. They must, therefore, develop neuronal 
processes (axons and dendrites) that allow them to communicate with other neurons. Each cell 
has many dendrites and a single axon that can extend to a certain distance from the cell. Once the 
axon has reached its target, the connections called synapses are formed with the target cell. 
Synaptogenesis consists of three phases: the immature synapses are formed between the axons 
and the dendrites; therefore, the synapses undergo maturation and convert from to silent into an 
active state; finally, the synaptic number is reduced to the neuronal connections within the circuit 
(Craige et al., 2006; Budday et al., 2015).  
Although the production and migration of neurons are largely prenatal events, proliferation and 
migration of glial progenitors continue for a long time after birth, and differentiation and 
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maturation of these cells continue during childhood. Neuron-glia interactions are not yet fully 
defined, but these interactions play an important role in the functional organization of neural 
circuits during postnatal life. In the postnatal period, neurogenesis continues to a very limited 
degree; however, new neurons continue to emerge and migrate into the subventricular zone and 
the dentate gyrus of the hippocampus (Stiles and Jernigan, 2010). These exceptional forms of 
neurogenesis seem to continue throughout adult life but produce only a small percentage of the 
neuronal population (Ming and Song, 2011; Kempermann et al., 2018).    
 
1.2 Programmed cell death in neurodevelopment 
Programmed cell death (PCD) contributes to the development of the nervous system in an 
evolutionarily conserved manner. PCD is the basis of the neurotrophic theory, whereby cell death 
derives from a surplus of neurons (Yamaguchi and Miura, 2015). Much of the PCD occurs 
through apoptosis, a well-characterized genetic program that exhibits specific morphological 
characteristics such as membrane blebbing, nuclear and cytoplasmic withdrawal, condensation of 
chromatin and DNA fragmentation (Kerr et al., 1972; Yeo and Gautier, 2004; Yamaguchi and 
Miura, 2015). The components of the cellular apoptotic machinery can be classified into pro-
apoptotic regulators, such as BAX, BID, APAF-1, DIABLO and anti-apoptotic regulators, such 
as BCL-2, BCL-XL, apoptosis inhibitors (IAPs) and caspases, which belong to a family of 
cysteine proteases that are the key effectors of the process (Yamaguchi and Miura, 2015). The 
regulation of caspase activities is complex and derives from the interplay between the anti- and 
pro-apoptotic regulators (Yeo and Gautier, 2004). Executioner caspases, including CASPASE-
3/7, are physiologically activated by extrinsic death ligands or intrinsic signals such as DNA 
damage, survival factor deprivation, ER stress, abnormal ion flow or reactive oxygen 
overproduction (Figure 3) (Green et al., 2014; Yamaguchi and Miura, 2015).   
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Fig 3. Schematic representation of molecular pathways leading to apoptosis by effector caspase 
activation (Yamaguchi and Miura, 2015). 
 
Two important processes involve substantial loss of neural elements: naturally occurring cell 
death, which involves the normal loss of 50% or more of the neurons within a brain region; 
synaptic exuberance and pruning in which there is a massive excess production of connections 
followed by the systematic elimination of up to 50% of those connections. Both processes reflect 
non-pathological events that play an essential role in establishing the complex networks of the 
developing brain (Stiles and Jernigan, 2010). The uptake of neurotrophic substances protects 
against the apoptosis cascade (Levi-Montalcini, 1964; Oppenheim, 1989). Neurotrophic factors 
are produced by target neurons at synaptic sites and are taken up by the afferent neurons that make 
effective connections with the targets (Huang and Reichardt, 2001). During development, it is 
thought that neurons compete for neurotrophic resources. According to the neurotrophic 
hypothesis (Oppenheim, 1989), neurons that establish effective connections are able to obtain 
more neurotrophic factor and are more likely to survive. 
 
1.3 Regulatory landscape of human neurodevelopment 
Recent genome-wide profiling studies of the developmental transcriptome of the human brain by 
several groups (Johnson et al., 2009; Somel et al., 2009; Ip et al., 2010; Colantuoni et al., 2011; 
Kang et al., 2011; Lambert et al., 2011; Mazin et al., 2013; Miller et al., 2014; Pletikos et al., 
2014; Jaffe et al., 2015) revealed that the great majority of protein-coding genes (at least 86% 
according to Kang et al., 2011) and an ever-expanding number of non-coding genes are used at 
some point in the building of the human CNS. In particular, they evidenced remarkable 
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dynamicity of gene expression during prenatal and early postnatal development, accounting for 
approximately 2/3 of the variance in global expression. Transcriptional studies also demonstrated 
correlations between gene expression dynamics and the morphological and functional 
development of brain regions and, consequently, shed light on the timing of developmental 
processes and the onset of specific biological functions (Johnson et al., 2009; Kang et al., 2011; 
Parikshak et al., 2013; Willsey et al., 2013; Miller et al., 2014). For example, gene co-expression 
network analyses have revealed that the developmental brain transcriptome can be segregated into 
distinct modules or clusters of genes with highly correlated expression. Many transcriptional 
processes are shared and coordinated across different regions as the brain develops. In particular, 
the module enriched for genes associated with the neuronal specification is most highly expressed 
during the embryonic and early fetal periods, while the module enriched for genes associated with 
synaptic function and ion channels begins to rise in late fetal period and plateaus in early 
childhood. Recent approaches have successfully integrated the spatiotemporal dimensions of the 
human brain transcriptome with gene mutation discoveries to generate testable hypotheses about 
when and in which regions and/or cell types in the developing human CNS the expression of 
disease-associated genes converge. It is intriguing to speculate that selective dysfunction of 
spatially and temporally regulated gene expression may in part explain differences in the age of 
onset and affected neural circuits in neurological and psychiatric disorders (Silbereis et al., 2016). 
As an important layer of gene expression, the epigenetic mechanisms act in concert with trans 
and cis components of the regulatory circuitry and play a critical role in regulating spatiotemporal 
gene expression patterns (Maze et al., 2014; Nord et al., 2015; Shibata et al., 2015; Silbereis et 
al., 2016). These mechanisms, including DNA methylation, histone modifications, and non-
coding RNAs, can also be affected by various extrinsic factors, thus providing a molecular link 
between external cues and gene expression (Silbereis et al., 2016). DNA methylation of cytosine, 
primarily at CpG nucleotides, plays a key role in neural development and function. DNA 
methylation levels change rapidly during fetal development but slow down after birth and with 
aging (Numata et al., 2012; Silbereis et al., 2016). The accumulation of methylation in the non-
CpG context (mCH) happens during early postnatal development (first 2 years postpartum) and 
through adolescence, with a small decrease thereafter. Lister et al. (2013) noted that the 
accumulation of mCH and gene expression were negatively correlated; genes highly expressed in 
adult neurons lost both CpG and non-CpG methylation progressively during development (Lister 
et al., 2013). In addition to DNA methylation, histone modification is an essential mechanism for 
establishing cellular diversity and regulating the timing of developmental processes (Silbereis et 
al., 2016). Methylation (mono-, di-, and tri-) and acetylation are the most extensively studied 
modifications (Tessarz and Kouzarides, 2014). For example, Cheung and colleagues (2010) 
profiled histone 3 lysine 4 trimethylation (H3K4me3) across development in neuronal and non-
neuronal cells of the human prefrontal cortex. They highlighted significant remodelling during 
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postnatal development and the aging of prefrontal neurons. In particular, they observed higher 
levels of H3K4me3 methylation of NEUROD1 and several members of the cadherin and 
semaphorin families in newborns compared to older samples. Dysregulation of epigenetic 
modifications are associated with various human diseases, including neurodevelopmental 
disorders (Bale et al., 2010; Millan, 2013). In particular, an increasing number of mutations in 
histone lysine methylation-related genes have been identified as intellectual disability-associated 
genes (Ronan et al., 2013; Vissers et al., 2016). 
The correct gene expression regulation during development requires the intricate interplay 
between transcription factors, epigenetic modifications, and non-coding RNAs (ncRNAs). The 
latter represents a large, but poorly characterized component of the human transcriptome. 
ncRNAs play a critical role in transcriptional and post-transcriptional regulation of gene 
expression and affect the overall transcriptional landscape and proteomic diversity of a cell 
(O’Carroll and Schaefer, 2013; Morris and Mattick, 2014; Silbereis et al., 2016). ncRNAs can be 
classified as short or long RNAs, on the basis on their length. Short microRNAs (miRNAs) are a 
relatively well-known class of RNA whose mechanism of action has been unravelling. miRNAs 
bind their mRNA target based on sequence complementary and trigger the degradation or the 
translation of inhibition of the mRNA (O’Carroll and Schaefer, 2013; Silbereis et al., 2016). Long 
non-coding RNAs (lncRNAs) represents a relatively newly identified class of RNA. The 
lncRNAs can act as regulators at different levels: at the transcriptional level by means of 
chromatin remodeling mechanisms and histone modifications; at the post-transcriptional level 
through interaction with mRNAs, with consequent modulation of splicing, inhibition of protein 
synthesis, degradation of mRNAs and formation of endogenous siRNAs; they can interact with 
other biological molecules, modulating the activity of proteins, their localization and the 
formation of RNA-protein complexes; finally they can interact with miRNAs (Wilusz et al., 2009; 
Wu et al., 2013). Recent studies have shown that many miRNAs and lncRNAs are expressed in 
the human and non-human primate brain and are spatially and temporally regulated (Somel et al., 
2011; O’Carroll and Schaefer, 2013; Silbereis et al., 2016). A growing body of evidences 
emphasizes the role of lncRNAs in neurodevelopment and brain function, and a functional 
correlation with several neurodevelopmental, neurodegenerative and psychiatric diseases (for 
instance, see St Laurent and Wahlestedt, 2007; van de Vondervoort et al., 2013; Wu et al., 2013; 
Barry, 2014; Roberts et al., 2014; Tushir and Akbarian, 2014). For example, MIAT, also termed 
as Gomafu, exhibits deregulation in multiple diseases, including up-regulation in ischemic stroke 
and down-regulation in schizophrenia (Sun et al., 2018); BACE1-AS stabilizes the BACE1 
transcript, protecting it from RNA degradation through RNA–RNA pairing, and thus contributing 
to the progression of Alzheimer's (Clark and Blackshaw, 2014). 
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1.4 Role of neurotrophins in neuronal development 
Four neurotrophins have been characterized in mammals: nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) 
(Hallbook, 1999). They share sequence homology and structure similarity and evolved from a 
common ancestral gene (Hallbook, 1999).  
Neurotrophins act by binding their cognate NTRK receptors (Trk, tropomyosin-related kinase). 
NGF is specific for NTRK1; BDNF and NT-4 are specific for NTRK2; NT-3 activates NTRK3 
and it is also able to activate less efficiently each of the other NTRK receptors (Figure 4). 
 
Fig 4. Neurotrophins receptors and specific ligands (https://www.sinobiological.com/neurotrophin-
receptor-sinobio.html). 
 
Ligand engagement of NTRK receptors has been shown to result in phosphorylation of 
cytoplasmic tyrosine residues on the cytoplasmic domains of these receptors. Phosphorylation of 
other tyrosine residues promotes signalling by creating docking sites for adaptive proteins 
containing phosphotyrosine (PTB) or src-homology-2 (SH-2) binding patterns (Huang and 
Reichardt, 2001; Pawson and Nash, 2000). These adapter proteins couple NTRK receptors to 
intracellular signaling cascades, which include the Ras/ERK metabolic pathway (signal 
extracellular signal-regulated kinase), the phosphatidylinositol-3- kinase (PI-3 kinase) / AKT-
kinase and the phospholipase C (PLC) -γ1 (Figure 5) (Reichardt and Fariñas, 1997; Kaplan and 
Miller, 2000; Huang and Reichardt, 2001). 
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Fig 5. Schematic diagram of NTRK receptor-mediated signal transduction pathways. In this diagram, 
adaptor proteins are red, kinase green, small G proteins blue, and transcription factors brown. (Huang and 
Reichardt, 2001). 
 
Each neurotrophin also binds to the low-affinity p75NTR (NGFR) receptor, which is a member 
of the tumor necrosis factor receptor superfamily (Frade and Barde, 1999; Huang and Reichardt, 
2001). NGFR interacts with proteins, including TRAF6, RhoA, NRAGE (neurotrophin receptor-
interacting MAGE homologue), SC-1, and NRIF, and regulates gene expression, cell cycle, and 
growth cone motility. Binding of neurotrophins to NGFR has also been shown to activate the Jun 
kinase pathway, which can be inhibited by activation of the NTRK receptors-dependent Ras-
phosphatidylinositol-3-kinase (PI3K) pathway by NTRK receptors. Most intriguing, both in vitro 
and in vivo evidences indicates that ligand engagement of NGFR can directly induce neuronal 
death via apoptosis (Frade and Barde 1999; Friedman, 2000; Huang and Reichardt, 2001) (Figure 
6). 
 
Fig 6. Schematic diagram of p75NTR-mediated signal transduction pathways. In this diagram, adaptor 
proteins are red, kinase green, small G proteins blue, and transcription factors brown. (Huang and Reichardt, 
2001). 
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Neurotrophins regulate development, maintenance, and function of vertebrate nervous systems 
(Huang and Reichardt, 2001). They are initially synthesized as precursor proteins (pro-
neurotrophins), which are processed intracellularly to be secreted mostly in a mature, biologically 
active form (Mowla et al., 1999; Mowla et al., 2001; Lu et al., 2005; Matsumoto et al., 2008). 
During development, neurotrophins stimulate the formation of appropriate synaptic connections, 
controlling the direction and rate of axon growth (Wang and Poo, 2005; Li et al., 2005), as well 
as the shape of dendritic arbores and spines (Ji et al., 2005; Melo et al., 2013). 
The neurotrophin BDNF plays a central role both in neuronal development and in the adult 
nervous system, and dysfunction in its signalling may contribute to several neurodegenerative 
disorders (Pruunsild et al., 2007). BDNF interaction with NTRK2 receptor activates three 
signaling pathways: PI3K-Akt (PI3K, phosphatidyl inositol-3 kinase), Ras-MAPK (MAPK, 
mitogen-activated protein kinase), and PLCγ-Ca+ (PLC, phospholipase C) (Duman and Voleti, 
2012). It is also known to regulate a large spectrum of processes of the nervous system, including 
cell survival, growth and differentiation (Casaccia-Bonnefil et al., 1999; Bibel and Barde, 2000; 
Huang and Reichardt, 2003; Park and Poo, 2013; Suliman et al., 2013; Zagrebelsky and Korte, 
2014), synaptic plasticity of neurons and LTP (Xu et al., 2000; Bramham and Messaoudi, 2005; 
Gottmann et al., 2009; Minichiello, 2009; Mizui et al., 2014; Zagrebelsky and Korte, 2014; Leal 
et al., 2015). The essential role of BDNF in neuronal processes during development and 
adulthood, support its potential therapeutic use in the treatment of both neurological and 
psychiatric disorders (Pruunsild et al., 2007; Nagahara and Tuszynski, 2011; Weissmiller and Wu, 
2012). In fact, BDNF exerts potent pro-survival effects in models of neurological diseases such 
as Parkinson’s (PD) (Howells et al., 2000; van der Kolk et al., 2015), Huntington’s (HD) (Zuccato 
et al., 2008; Jiang et al., 2013), and Alzheimer’s (AD) diseases (Holsinger et al., 2000; Michalski 
and Fahnestock, 2003; Peng et al., 2005; Faria et al., 2014), as well as depression and other 
psychiatric disorders (Karege et al., 2002; Aydemir et al., 2005; Gonul et al., 2005; Cunha et al., 
2006).  
 
1.5 Immediate Early genes in brain 
Immediate-early genes (IEGs) are genes that are induced rapidly and transiently in response to a 
wide range of cellular stimuli. They act in many biological processes: regulation growth, 
differentiation and cell cycle. Because of the wide variety of extrinsic stimuli to which they 
respond, their mechanism of action can vary depending on the stimulus received, its duration and 
the type of cell (Bahrami and Drabløs, 2016).  
IEGs play a key role in brain development; in particular their expression is selectively and rapidly 
increased in certain neurons of specific brain regions, associated to the formation of memory and 
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learning (Minatohara et al., 2015). They are also involved in important processes such as neuronal 
plasticity, which persists even in adulthood and therefore is not limited only to the early stages of 
development (Pérez-Cadahìa et al., 2011).  
Approximately 30-40 neuronal IEGs have been identified; 10-15 are regulators, whose protein 
products are classified as inducible transcription factors, such as C-FOS and EGR1 (Davis et al., 
2003). C-FOS is involved in cell proliferation and differentiation after extracellular stimuli, and 
its deregulation has been often associated to oncogenic progression (Velazquez et al., 2015). Only 
40% of knockout c-Fos mouse embryos survive until birth showing the importance of this gene 
for development (Velazquez et al., 2015). EGR1 is a transcription factor widely studied in adults, 
where it plays a clear role in synaptic plasticity (Adams et al., 2017). Several evidences in 
different cell lines led to hypothesize that EGR1 can play a role in the development of neurons 
(Milbrandt, 1987; Aliperti and Donizetti 2016). ARC (also knowns as Arg3.1), NPAS4 and 
HOMER1a (a shorter variant of Homer1) are all induced by neuronal activity and they are 
therefore considered IEGs (Xiao et al., 1998; Korb and Finkbeiner, 2011; Kim et al., 2018). ARC 
is not a transcription factor but acts as an effector involved in various neuronal signaling 
pathways. ARC mRNA is rapidly transcribed in response to neuronal activity, and precisely 
targeted to activated synapses in neuronal dendrites (Farris et al., 2014; Kim et al., 2018). NPAS4 
is a brain-specific transcription factor, which plays a role in the development of inhibitory 
synapses by regulating the activity-dependent gene programs in cultured neurons (Kim et al., 
2018). HOMER1a is primarily located at the postsynaptic density where it competes with other 
constitutively expressed Homer proteins for the interaction with Homer-binding proteins. As 
such, HOMER1a negatively regulates excitatory synapse structure and function (Sala et al., 2003; 
Kim et al., 2018). 
Alterations in the expression of IEGs have been associated with various cognitive disorders, such 
as autism, schizophrenia and dementia (Thiel and Cibelli, 2002). 
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2. AIM OF THE STUDY 
The central nervous system (CNS) is a large network of interconnecting and intercommunicating 
cells that form functional circuits and is responsible for intellectual and cognitive functions. 
Generation of the CNS occurs during embryonic development from a pool of immature 
progenitors that will give rise to all the neurons in the brain and spinal cord. During neuronal 
development transcriptional regulation plays fundamental role in each step of the process from 
neural fate determination to complete neuronal maturation. At a molecular level, this process is 
coordinated by transcription factors involved in all the cellular processes, including cell cycle 
exit, migration, survival, and acquisition of neuronal features, such as dendrites and axon 
maturation, and functional synapses. Dysfunction of gene expression regulation during critical 
developing periods lead to neurodevelopmental abnormalities and mental disorders. Despite the 
progress on the molecular mechanisms controlling neuronal development, a lot remains to be 
clarified about regulation of gene expression and regulation of transcriptional activity underlying 
this phenomenon. This is especially true considering that beyond classical transcription factors 
and miRNA, it is now emerging another recently identified class of molecules, the long non-
coding RNA (lncRNA), as a fundamental element of gene expression regulation underlying 
neuronal development.  
Each stage of neuronal maturation requires an integration of cell-intrinsic genetic programs and 
the extrinsic influences such as the effects of neurotrophic factors. Among neurotrophins, BDNF 
has been shown to be essential for the correct development of the brain, playing an important role 
in numerous cellular processes, such as axon migration, regulation of the size and number of 
dendritic spines, synaptogenesis and cellular survival.  
In an effort to identify long non-coding RNA involved in the BDNF function during neuronal 
development, we carried out high-throughput experiments reported in the part I of the present 
thesis. In particular, we focused on those transcriptional events occurring immediately after 
BDNF stimulus, considering that they play critical roles in long-lasting neuronal changes by 
regulating a plethora of target genes. We took advantages from the use of a popular human 
neuroblastoma cell line (SH-SY5Y) as an experimental model of neuronal development.   
The results of the part I provided the identification of coding and long non-coding RNA involved 
in the BDNF biology and thus likely important in the transcriptional programs occurring during 
neuronal development. In the second part of this thesis, we focused our attention on EGR1, one 
the coding genes engaged by BDNF. This gene encodes for a transcription factor whose role in 
the embryogenesis remains elusive. By using the recent and powerful molecular approach for 
genome editing, the CRISPR/Cas9, we provided preliminary investigation on the role of EGR1 
in the human neuronal development.  
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The high-throughput analysis reported in the part I allowed us to identify a lncRNA never 
associated to neuronal development, the LINC00473. With the aim to provide a characterization 
of this gene, in the part III of this thesis, we analyzed the evolutionary conservation of the 
sequence and the expression pattern regulation. In addition, to gain preliminary insights on the 
molecular mechanism of action, we generated a KO model for the LINC00473 gene. 
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3. MATERIALS & METHODS 
3.1 Cell cultures 
The human neuroblastoma cell line SH-SY5Y was used as a neuronal cell model. In particular, 
the N-enriched population of SH-SY5Y was obtained from the parental cell line by a procedure 
reported elsewhere (Piacentini et al., 1996; Bell et al., 2013; Aliperti and Donizetti 2016). The 
cells were grown and propagated in Dulbecco’s modified Eagle’s medium (DMEM, Euroclone®), 
supplemented with 2mM L-glutamine (Euroclone®), and a solution of 1% penicillin/streptomycin 
(Euroclone®) and 15% Fetal Bovine Serum (FBS, Euroclone®). 
The HEK293T cell line was grown and propagated in Dulbecco’s modified Eagle’s medium 
(DMEM, Euroclone®), supplemented with 2mM L-glutamine (Euroclone®), and a solution of 1% 
penicillin/streptomycin (Euroclone®) and 10% Fetal Bovine Serum (FBS, Euroclone®). 
 
3.2 Cellular treatments  
The N-enriched SH-SY5Y cells were differentiated by incubation in a low serum (1.5%) medium 
containing RA (retinoic acid, SIGMA–Aldrich®) 10µM. In particular, 8x105 cells were seeded in 
35mm plates and starved for 24h by reducing FBS. Then RA was added, and the medium was 
refreshed every 2 days. Untreated cells were grown in the presence of only dimethyl sulfoxide 
(DMSO) as vehicle control. After 6 days of differentiation, the medium containing RA was 
removed and substituted with a medium without FBS and with BDNF 10ng mL-1 (PeproTech®) 
for a specific time. 
In order to evaluate the effect of RA concentration, WT and EGR1-KO cells were treated with 
increasing doses of morphogen (3μM, 6μM and 10μM). 5x104 cells were seeded in 24-well plates 
and starved for 24h by reducing FBS from 15% to 1.5%. RA was then added to the different 
concentrations, and the cells were followed up to 6 days with observations under an optical 
microscope. 
For TPA differentiation, 8x105 N-enriched SH-SY5Y WT and EGR1-KO cells were seeded in 
35mm plates. The day after, the cells were treated with TPA (16nM) in a medium where the 
percentage of FBS was reduced from 15% to 1.5%. Untreated cells were grown in the presence 
of only dimethyl sulfoxide (DMSO). The medium was refreshed every 2 days.  
For FBS stimulation, 6x105 HEK293T cells were seeded in 35mm plates and starved for 24h by 
reducing FBS from 10% to 1.5%. After 24h of starvation, cells were stimulated with 15% FBS  
and collected after different time intervals as reported in the Results section. 
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3.3 RNA isolation, retrotranscription and quantitative PCR (qPCR) analysis 
For microarray analysis, total cellular RNA was isolated using an RNeasy® Mini Kit (QIAGEN) 
according to the RNeasy® Mini Handbook (QIAGEN). DNA contamination was efficiently 
removed by on-column DNAse digestion (QIAGEN).  
For the analysis of transcript levels, total cellular RNA was isolated using TRI-Reagent (SIGMA–
Aldrich®) according to the manufacturer’s instructions.  
The concentration and purity of the RNA sample were assessed using NanoDrop® 1000 (Thermo 
Scientific). cDNA was synthesized from 1μg of total RNA using an Invitrogen SuperScriptIII® 
reverse transcriptase kit (Invitrogen). qPCR validation was performed on independent biological 
replicates in triplicate. Real-time PCR was performed using the SYBR green method and an 
Applied Biosystems 7500 System. The reaction mixture contained 50ng of cDNA template and 
400nM of each forward and reverse primer in a final volume of 15μL. PCR conditions included 
a denaturation step (95°C for 10min) followed by 40 cycles of amplification and quantification 
(95°C for 35s, 60°C for 1min). Relative gene expression levels were normalized to the reference 
gene Hypoxanthine Phosphoribosyl Transferase 1 (HPRT1) for microarray validation, and to the 
gene Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) for the other analyses. It was 
calculated by the 2 – ΔΔCt method. The sequences of the primers used are reported in Table 1. 
 
3.4 Microarray analysis 
Microarray experiments were performed on biological triplicate samples. Total RNA quality was 
assessed by an Agilent 2100 Bioanalyzer (Agilent Technologies). Microarray hybridizations were 
performed by the Transcriptomics and Genomics core facility of the Department of Emergency 
and Organ Transplants (DETO) in the Nephrology Unit at the University of Bari Aldo Moro in 
Italy. The labeled cRNA was produced using a Low Input Quick Amp Labeling (LIQA) kit 
(Agilent Technologies) and hybridized for 17 hours at 65°C on an Agilent SurePrint G3 8x60K 
custom lncRNA expression array (Agilent Technologies). This array contains two probes for 
22,001 lncRNAs targeting the Gencode v15 human lncRNA annotation, together with one probe 
for 17,535 randomly chosen protein-coding transcripts. After hybridization, the slide was washed 
according to Agilent protocols and scanned using a High-Resolution Microarray C Scanner 
(Agilent Technologies). The image file was processed using Agilent Feature Extraction software 
(v10.7.3). The microarray grid was correctly placed, and outlier pixels (which were rejected) and 
inlier pixels were identified. Normalization was performed according to the Quantile method. The 
differentially expressed probes were selected using a moderated t-test with a p-value cut-off of 
0.05. 
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3.5 lncRNAs classification and functional analysis 
The LNCipedia database (http://www.lncipedia.org/) (Volders et al., 2015) was used for 
retrieving the transcript ID, gene ID, and alternative gene name of the differentially expressed 
lncRNAs. Differentially expressed lncRNAs were classified by considering their position relative 
to adjacent protein-coding genes as reported by Mattick and Rinn (2015). The differentially 
expressed lncRNAs were analysed by CPAT software (http://lilab.research.bcm.edu/cpat/) (Wang 
et al., 2013) to assess their protein-coding potential. For the functional analysis of the lncRNAs, 
a list of nearby potentially regulated genes was retrieved using the computational tool GREAT 
(Genomic Regions Enrichment of Annotations Tool; 
http://bejerano.stanford.edu/great/public/html/) (McLean et al., 2010). Functional enrichment 
analysis for the predicted target genes and differentially expressed coding genes was performed 
using the DAVID system (Database for Annotation, Visualization and Integrated Discovery; 
http://david.abcc.ncifcrf.gov/) (Dennis et al., 2003), which uses Gene Ontology (GO) to identify 
the molecular function represented in the gene profile (Dennis et al., 2003). For all DAVID 
analyses, the significance of enrichment of each GO term was assessed by a p-value of <0.05 and 
ranked by the number of differentially expressed genes (count). The lncRNAs were analyzed with 
the lncRNome software (http://genome.igib.res.in/lncRNome) (Bhartiya et al., 2013) to identify 
possible interactions with proteins. The database contains information about 6,800 binding sites 
for proteins obtained from PAR-CLIP and CLIP-seq analyses. I obtained a list of potentially 
regulated miRNAs from lnCeDB (http://gyanxet-beta.com/lncedb/) (Das et al., 2014), a database 
that provides human lncRNA that can potentially act as competitive endogenous RNAs (ceRNAs) 
and interfere with the pathway of miRNAs. These miRNAs were analyzed by miR2Disease 
(http://www.mir2disease.org/) (Jiang et al., 2009) to find miRNAs deregulated in human diseases. 
The potentially regulated miRNAs were also analyzed by miRTarBase 
(http://mirtarbase.mbc.nctu.edu.tw/) (Chou et al., 2018) to find their experimentally validated 
mRNA targets.  
 
3.6 Generation of EGR1 and LINC00473 KO cell lines 
The knockouts for the EGR1 gene in an N-enriched SH-SY5Y cell line and the LINC00473 gene 
in the HEK293T cell line were obtained using the CRISPR/Cas9 procedure as reported by Ran et 
al. (2013). Briefly, forward and reverse oligonucleotides (Table 2) for the gRNA were designed 
from the online CRISPR design tool (http://crispr.mit.edu/) and inserted in the all-in-one vector 
pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene plasmid #62988) for EGR1 knockout and in the 
all-in-one vector AIO-PURO (Addgene plasmid #74630) for the LINC00473 gene. The first 
strategy was designed to obtain an INDEL mutation in the ORF; the second strategy was based 
on the use of an all-in-one vector with the Cas9 Nickase and two gRNAs in order to remove a 
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wider region, avoiding off-targets. Subsequently, the vectors were transfected into the cells using 
Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
After 24h of transfection, the cells were cultured under a puromycin selection (1µg mL-1) for 48h. 
The surviving cells were left to propagate in the plate and then transferred into a 96-well plate for 
single clone selection by serial dilution. The monoclonal population carrying EGR1 and 
LINC00473 mutated sequences was selected by sequence analysis of genomic region of interest. 
The genomic DNA was isolated by Quick-gDNATM Miniprep kit (ZYMO RESEARCH) and the 
region of interest was amplified using specific primers pair (Table 2). The PCR products were 
then subcloned in the pGEM®-T Easy Vector (Promega) and several independent clones were 
subjected to Sanger sequencing. 
 
3.7 iPSCs 
iPSCs were grown and propagated under feeder-free conditions in StemMACSTM IPS-Brew XF 
Basal medium (SB, MACS® Media), supplemented with StemMACSTM IPS-Brew XF 50X 
supplement (MACS® Media). The medium was changed every day.  
Cells were transfected with all-in-one vector pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene 
plasmid #62988) containing the validated EGR1 gRNA. AmaxaTM Human Stem Cell 
NucleofectorTM Kit 1 (LONZA) was used for transfection according to the manufacturer’s 
instructions. After 48h of transfection, the cells were cultured under a puromycin selection (0.5µg 
mL-1) for 48h. Finally, single clones were picked and transferred in a 48-well plate. The genomic 
DNA was isolated using QIAamp DNA Blood Mini kit (QIAGEN) and the region of interest was 
amplified by using specific primers pairs (Table 2). The PCR products were sequenced to check 
the generation of mutation. 
 
3.8 Western Blotting 
N-enriched SH-SY5Y WT and EGR1-KO cell pellets were lysed in RIPA buffer (50mM Tris-
HCl pH 8.8, 150mM NaCl, 1mM EDTA, 0.1% SDS, 1% Triton X-100) containing protease 
inhibitors (Roche), incubated on ice for 30min and centrifuged at 14000rpm for 10min at 4°C. 
The supernatant was collected and used for protein quantification by Bradford assay (BIO-RAD). 
30μg of protein lysate for each sample was electrophoresed in SDS gel (10% acrylamide) and 
blotted on to a nitrocellulose membrane. The transferred membranes were blocked with 3% non-
fat milk (BIO-RAD) in TBST buffer (100mM Tris-HCl pH 8, 1.5M NaCl, 1% Tween) for 1h at 
room temperature (RT) and incubated with specific primary antibodies in TBST with 3% non-fat 
milk (BIO-RAD) overnight at 4°C. After several washes with TBST, the membranes were 
incubated with the corresponding secondary antibodies in the same buffer. After several washes, 
27 
 
immunoreactive bands were visualized using ECL detection kit (Euroclone®) according to the 
manufacturer’s instructions. Primary and secondary antibodies are listed in Table 3. 
 
3.9 EGR1 iper-expression experiments: cloning, transfection and subcellular 
fractionation protocol 
The CDS of the EGR1alternative isoform (EGR1 Δ141-278) was amplified by PCR using cDNA 
samples obtained by RNA extracted from N-type SH-SY5Y cells treated with RA for 6 days as a 
template. The reaction mixture contained 50ng of cDNA template and 400nM of each forward 
and reverse primer spanning from the start codon to the stop codon, in a final volume of 20μL. 
The PCR conditions included a denaturation step (95°C for 2min) followed by 38 cycles of 
denaturation, annealing and elongation (95°C for 30s, 60°C for 40s and 68°C for 1min). The PCR 
product was isolated and cloned into pCMV3 expression vector by using restriction enzymes KpnI 
and XbaI. 
The pCMV6-EGR1 vector (SC128132, ORIGENE) and the pCMV3 with CDS of the alternative 
isoform of EGR1 were used for iper-expression experiments. Both expression vectors were 
transfected in HEK293T cells using Lipofectamine 3000 (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. After 24h of transfection, cell pellets were lysed in a fractionation 
buffer (20mM HEPES pH 7.4, 10mM KCl, 2mM MgCl2, 1mM EDTA, 1mM EGTA, 1mM DTT) 
containing protease inhibitors (Roche), incubated on ice for 20min, and centrifuged at 3000rpm 
for 5min at 4°C. The pellet contained nuclei and the supernatant contained cytoplasm proteins. 
Supernatant containing cytoplasmic proteins was transferred into a fresh tube, while the pellet of 
nuclei was washed with fractionation buffer and centrifuged at 3000rpm for 10min at 4°C. Finally, 
the pellet of nuclei was suspended in TBS buffer (100mM Tris-HCl pH 8, 1.5M NaCl) with 0.1% 
SDS and sonicated. 
 
3.10 Immunofluorescence analysis 
HEK293T cells were grown on coverslips, fixed in 4% paraformaldehyde (PFA), permeabilized 
in 0.3% PBS-Triton X-100 for 20min at RT, and then blocked in 3% PBS-BSA for 30min at RT. 
Cells were subsequently incubated with primary antibodies for 1.5h at RT in 3% PBS-BSA and 
then rinsed with PBS 1X. Specific secondary antibodies conjugated with fluorophores were used 
for 1h at RT in 3% PBS-BSA. Finally, the cells were washed in PBS 1X. Nuclei were stained 
with DAPI and coverslips were mounted using glycerol 50% in PBS 1X. Primary and secondary 
antibodies are listed in Table 4. 
28 
 
3.11 Statistical analysis 
The results from independent biological replicates in triplicate are expressed as mean ± SEM. 
Statistical analysis of the qPCR data was carried out using a two-tailed t test (Prism 6 software) 
with a p-value cut-off of 0.05. 
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TABLES 
 
Table 1. Sequences of primers used for qPCR analysis. 
Gene symbol Ensemble code Primer sequence 
HPRT1 ENSG00000165704 F_5’- CGGGGACTTTGGGATGTC -3’ 
R_5’- CGCTTTCCGTCGTGAATTTC -3’ 
GAPDH ENSG00000111640 F_5’- CGGGGACTTTGGGATGTC -3’ 
R_5’- CGCTTTCCGTCGTGAATTTC -3’ 
NTRK2 ENSG00000148053 F_5’- CGGGGACTTTGGGATGTC -3’ 
R_5’- CGCTTTCCGTCGTGAATTTC -3’ 
ARC ENSG00000198576 F_5’- GAGTCCTCAAATCCGGCTGA -3’ 
R_5’- GCACAGCAGCAAAGACTTT -3’ 
SIK1 ENSG00000142178 F_5’- AAGACCGAGAACCTCCTGCT -3’ 
R_5’- GTGGACAGAGGCTCTCCTGA -3’ 
NR4A1 ENSG00000123358 F_5’- CACAGCTTGCTTGTCGATGT -3’ 
R_5’- GGTTCTGCAGCTCCTCCAC -3’ 
ATF3 ENSG00000162772 F_5’- ATCACAAAAGCCGAGGTAGC -3’ 
R_5’- TCCTTCTTCTTGTTTCGGCAC -3’ 
EGR1 ENSG00000120738 F_5’- GAGCAGCCCTACGAGCAC -3’ 
R_5’- GGCCACAAGGTGTTGCCA -3’ 
NR4A3 ENSG00000119508 F_5’- TTTGGAGCTGTTTGTCCTCA -3’ 
R_5’- CACTCCCCAAATCCACGAAG -3’ 
RHOB ENSG00000143878 F_5’- TTCGAGAACTATGTGGCCGA -3’ 
R_5’- GCACATGAGAATGACGTCGG -3’ 
SYBU ENSG00000147642 F_5’- AGAGCAGAGAGTTCAACCCC -3’ 
R_5’- AGCATCTGAGGGTGTCTTCA -3’ 
LINC00473-202 ENST00000455853 F_5’- GTCAGCATACTTTGGCGGAC -3’ 
R_5’- GTTGGTGCACGTGGGAGT -3’ 
RP11-182L21.2 ENST00000431300 F_5’- CACTTTGAGGTTCCCACTGC -3’ 
R_5’- TTGATGGCAGGGAGACGC -3’ 
LINC01089 ENST00000545885 F_5’- AGCAGAACGTGAGGGTGTAA -3’ 
R_5’- AGAGTCAAACTAGGCCTGCC -3’ 
HAND2-AS ENST00000505032 F_5’- TACGAAGACCTTGGGCGATT -3’ 
R_5’- GCGTTTAATGGTTCCCCTCC -3’ 
lnc-NPAS4 ENST00000526186 F_5’- TAGACCACCTGAGGATGACC -3’ 
R_5’- AGAGGGCTGTCAAAGTGTGA -3’ 
MIAT ENST00000423278 F_5’- CATGTGGTTCCAGACACGTT -3’ 
R_5’- CCTTCTGTCTCCTCTGTCCC -3’ 
CYP26a1 ENSG00000095596 F_5’- GCAGCCACATCTCTGATCACT -3’ 
R_5’- TGTTGTCTTGATTGCTCTTGC -3’ 
RARα ENSG00000131759 F_5’- CGTGTCTCTCTGGACATTGA -3’ 
R_5’- CCGAAGCCAGCGTTGTGCAT -3’ 
RARβ ENSG00000077092 F_5’- ATCCGAAAAGCTCACCAGGA -3’ 
R_5’- CTGAATTTGTCCCAGAGGCC -3’ 
RARγ ENSG00000172819 F_5’- AGGAATCGCTGCCAGTACTG -3’ 
R_5’- GCTTTGCTGACCTTGGTGAT -3’ 
BDNF ENSG00000176697 F_5’- ACACAAAAGAAGGCTGCAGG -3’ 
R_5’- TGCTATCCATGGTAAGGGCC -3’ 
NGFR ENSG00000064300 F_5’- GAGCCTGCATGACCAGCA -3’ 
R_5’- GCAGAGCCGTTGAGAAGC -3’ 
EGR1 Δ141-278 ENSG00000120738 F_5’- GAGCAGCCCTACGAGCAC -3’ 
R_5’- GTGCGGCTCTCCAGGGAA -3’ 
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Table 2. Sequences of gRNAs and genotyping primers. 
Name Sequence 
EGR1 gRNA TOP_5’- CACCGCTGCAGATCTCTGACCCGTT -3’ 
BOTTOM_5’- AAACAACGGGTCAGAGATCTGCAGC -3’ 
EGR1 sequencing 
primers 
F_5’- CCGACACCAGCTCTCCAG -3’ 
R_5’- CTGCGGTCAGGTGCTCGTAG -3’ 
LINC00473-202 
gRNA_A 
TOP_5’- ACCGTGGGGGTGCTTCCTCGTTCC -3’ 
BOTTOM_5’- AAACGGAACGAGGAAGCACCCCCA -3’ 
LINC00473-202 
gRNA_B 
TOP_5’- ACCGTGAGTCTACGTGCTATAGCC -3’ 
BOTTOM_5’- AAACGGCTATAGCACGTAGACTCA -3’ 
LINC00473-202 
sequencing primers 
F_5’- GAACTGTCGGCTGCGGC -3’ 
R_5’- TTCTCCAGTTACCACCCACC -3’ 
 
 
 
Table 3. Primary and secondary antibodies for Western Blot. 
Antibody Dilution 
Anti-EGR1 Polyclonal Antibody (Immunobiological Sciences),  
rabbit (AB-83620) 
1:1000 
Anti-GAPDH Monoclonal Antibody (Immunological Sciences),  
mouse (MAB-91903) 
1:5000 
Donkey Anti-rabbit IgG Secondary Antibody, HRP Conjugate  
(A120-108P) 
1:2000 
Goat Anti-mouse IgM Secondary Antibody, HRP Conjugate  
(BA1075) 
1:5000 
 
 
 
Table 4. Primary and secondary antibodies for Immunofluorescence. 
Antibody Dilution 
Anti-EGR1 Polyclonal Antibody (Boster Bio),  
rabbit (PA2177) 
1:100 
Anti-Tubulin beta-III Monoclonal Antibody (Elabscience®),  
mouse (E-AB-20095) 
1:200 
Goat Anti-Rabbit IgG Secondary Antibody, CY5 Conjugate  
(Bethyl, A120-201C5) 
1:500 
Sheep Anti-Mouse IgG Secondary Antibody, FITC Conjugate  
(Bethyl, A90-146F) 
1:500 
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4. RESULTS 
PART I 
Identification and preliminary characterization of genes involved in Early 
Response to BDNF Stimulation 
4.I.1 Identification on new players in early response to BDNF stimulation 
The original SH-SY5Y cell line comprises at least two morphologically and biochemically 
distinct phenotypes: neuroblastic (N-type) and a low proportion of epithelial-like (S-type; Encinas 
et al., 2000) phenotypes. Taking into account that the expression level of long non-coding RNA 
is much lower compared to coding RNA, and that even little variation in their amount could have 
a great functional impact, we decided to work on a more homogenous population by performing 
an enrichment procedure to isolate the N-subtype cells (see Materials and Methods). To check the 
efficacy of the enrichment procedure, we analysed the N-type enriched population before and 
after RA treatment. In fact, during RA treatment, N-type cells undergo morphological changes, 
while S-type cells do not change their shape and progressively increase their percentage in the 
population. As shown in Figure 7 (left panel), in their undifferentiated state, N-type cells have 
small, rounded cell bodies with short neuritic processes, while S-type cells are larger and flatter 
with a large cytoplasmic/nuclear ratio (Figure 7, left panel). After the enrichment procedure, the 
N-type cells appeared clearly isolated in the cell plate by microscopy observation of the cell shape 
(Figure 7, middle panel). The enrichment was better evaluated and confirmed after RA-induced 
differentiation, when the N-type cells became morphologically more like primary neurons (Figure 
7, right panel). 
 
Fig 7. N-enrichment procedure for SH-SY5Y cells. Left panel: photomicrograph showing the original 
SH-SY5Y population including both N-type and S-type cells; middle panel: photomicrograph showing the 
N-type-enriched SH-SY5Y population; right panel: photomicrograph showing the morphological changes 
of the N-type cells after 6 days of RA-induced differentiation. 
 
We sought to unravel the gene expression changes occurring immediately after BDNF 
stimulation, considering that the genes involved in this initial phase play critical roles in long-
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lasting neuronal changes during development by regulating many downstream target genes. In 
particular, we used microarray technology to survey long non-coding RNAs and coding RNAs 
involved in the BDNF function. With this scope, we preliminary validated our experimental 
model by assessing the BDNF high-affinity receptor NTRK2 expression level. In fact, it is 
reported that RA induces the expression of the NTRK2 in SH-SY5Y cells, making them 
responsive to BDNF (Kaplan et al., 1993; Encinas et al., 2000). The results of the qPCR analysis 
reported in the Figure 8, showed that the N-enriched population responded to RA stimulation 
increasing NTRK2 expression with the highest level after 6 days of treatment.  
 
Fig 8. Analysis of NTRK2 mRNA level after RA treatment by qPCR analysis. NTRK2 expression level 
in N-enriched SH-SY5Y cells differentiated with RA for 5 and 6 days; time (0d) represented the 
undifferentiated cells. NTRK2 gene expression level was normalized to the reference transcript (GAPDH) 
and calculated by the 2 – ΔΔCt method. The sample at time 0d was used as a calibrator. The results from 
independent biological replicates are expressed as mean of fold change ± SEM. Statistical analysis of the 
qPCR data was carried out using a two‐tailed t test. Significance of difference from time 0d (*p < 0.05) is 
shown. (d): days of RA treatment. 
 
Based on the qPCR results, we decided to perform the BDNF stimulation after 6 days of RA 
treatment. In order to identify the most appropriate time point for the immediate early response 
to BDNF treatment, we carried out a preliminary investigation of the expression pattern of three 
immediate early genes downstream of BDNF signalling ARC (Activity-Regulated Cytoskeleton-
Associated Protein), SIK1 (Salt-Inducible Kinase 1) and NR4A1 (Nuclear Receptor Subfamily 4). 
The expression of all three analyzed genes was induced by BDNF, with the transcript level change 
showing a peak after 1h of the neurotrophin treatment (Figure 9).  
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Fig 9. Expression analysis for 3 immediate early genes after BDNF stimulation. Expression level 
change in N-enriched SH-SY5Y cells after BDNF stimulation at the indicated time points for ARC (A), 
SIK1 (B), and NR4A1 (C). Time (0h) represented cells after 6 days of RA-induced differentiation. Gene 
expression level was normalized to the reference gene (GAPDH) and calculated by the 2 – ΔΔCt method. The 
sample at time 0h was used as a calibrator. The results from independent biological replicates are expressed 
as mean of fold change ± SEM. Statistical analysis of the qPCR data was carried out using a two‐tailed t 
test. Significance of difference from time 0h (*p < 0.05) is shown. 
 
In light of these results, we carried out a microarray analysis on RNAs extracted after 1h of BDNF 
treatment. The array used for the analysis is characterized by probes designed on GENCODE v15 
lncRNA annotation. This platform enables the analysis of gene expression changes for a total of 
22,001 lncRNAs and 17,535 genes encoding proteins. I found that many lncRNAs and coding 
genes significantly (p-value < 0.05) changed their transcript level after 1h of BDNF treatment. A 
fold change of > 1.5 was found in 41 lncRNAs (25 up and 17 down regulated) and 40 mRNAs 
(31 up and 9 down regulated) (Table 5). 
 
                       Transcript  number differentially expressed FC ≥ 1.5 
 
                          lncRNA    22,001                  155                                   41    
                           mRNA    17,535                  238                                 40 
Table 5. Summary of microarray analysis. 
 
A panel of both differentially expressed lncRNAs and mRNAs with fold change above 1.5 was 
validated by qPCR (Figure 10). 
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Fig 10. qPCR validation of some differentially expressed mRNA and lncRNAs (Aliperti and 
Donizetti, 2016). 
 
The differentially expressed lncRNAs were classified in accordance with the definition reported 
in the Materials and Methods section. Most differentially expressed lncRNAs were included in 
the intergenic and antisense classes (Table 6). 
Class Number 
Intergenic 19 
Antisense 13 
Overlapping 9 
Bidirectional 1 
Table 6. Summary of lncRNAs classification. 
 
It is interesting to note that the vast majority of top regulated coding transcripts with fold changes 
above 2 are classical immediate early genes (IEGs); many of these genes are involved in different 
biological processes in response to various neural stimuli, such as NR4A3, ARC, EGR1 
and DUSP5 (Table 7).  Notably, two of the top regulated lncRNAs (C6orf176 and MIAT) have 
also been shown to have an expression pattern that resembles the kinetics of immediate early 
response genes (Reitmair et al., 2012; Barry et al.  2014). 
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coding  regulation  FC   lncRNA     regulation   FC 
 
NR4A3  up  9.2   C6orf176     up   3.8 
ARC  up  8.3   lnc-NPAS4-1     up   3.1 
RHOB  up  4.3   lnc-WDR1-1     up   2.8 
FAM46A          up  3.6   IGFBP7-AS1     up   2.1 
EGR1  up  3.0   lnc-ZSCAN10-4   up   2.1 
DUSP5  up  3.0   MIAT-003     down  2.1 
KLF10  up  2.3   MIAT-001     down  2.0 
MAP3K14 up  2.0   lnc-RHOF-1     down  2.0 
              F3   up   2.0 
Table 7. Top regulated coding and long non-coding transcripts with fold change above2. 
 
lncRNAs belong to a relatively recent class of RNA, and many important features regarding their 
origin and role remain largely unexplored. One of the most interesting debate is over the 
possibility that some lncRNAs encode for evolutionary new peptides/proteins. In this regard, we 
submitted the 41 differentially expressed lncRNAs to the analysis of CPAT software 
(http://lilab.research.bcm.edu/cpat/) (Wang et al., 2013) to assess their protein-coding potential 
(Table 8). We found that 38 lncRNAs have a coding probability value below the cut off (0.364), 
while the remaining 3 lncRNAs have a coding probability value above the cut off. Among these 
three transcripts, C6orf176 had the highest fold change in our microarray analysis.  
Alternative gene 
name 
RNA size ORF 
size 
Coding 
Probability 
Coding 
Label 
FC (Abs) 
C6ORF176 1822 561 0.47 yes 3.40 
RP11-867G23.10 637 123 0.006 no 3.11 
RP11-448G15.3 3510 297 0.03 no 2.76 
MIAT 9942 309 0.01 no 2.09 
IGFBP7-AS1 1389 168 0.0001 no 2.09 
RP11-473M20.16 748 120 0.003 no 2.07 
MIAT 10215 300 0.02 no 2.03 
AC084018.1 559 144 0.002 no 2.00 
AC093673.5 648 78 0.03 no 1.95 
AC084018.1 875 270 0.04 no 1.93 
RP11-471J12.1 514 186 0.02 no 1.92 
RP11-466F5.8 2149 159 0.03 no 1.87 
MIAT 10142 300 0.02 no 1.84 
HOXD-AS1 609 171 0.01 no 1.81 
MIAT 10068 309 0.01 no 1.75 
RP4-564F22.5 2004 363 0.01 no 1.74 
MALAT1 480 120 0.007 no 1.73 
NR_026991.1 2193 294 0.16 no 1.73 
AC002310.7 1488 324 0.31 no 1.72 
MALAT1 1519 141 0.002 no 1.71 
AC084018.1 479 171 0.08 no 1.70 
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Table 8. Results of CPAT analysis (Aliperti and Donizetti, 2016). 
 
Five lncRNAs with a fold change above 1.5 were hypothesized to play a role in physiological and 
pathological processes in neuronal cells and/or as a regulators of gene expression (Table 9). 
Gene 
symbol 
  Regulation Function 
MALAT1 
(Neat2) 
downn Control of the expression of genes involved in synapse function      
(Bernard et al., 2010). Down-regulation led to cell arrest in the 
G1/S or G2/M phase (Yang et al., 2013). 
MIAT 
(Gomafu) 
down Down-regulated in response to neuronal activation and involved in 
schizophrenia-associated alternative splicing (Barry et al., 2014). 
Decreased in the medial prefrontal complex following fear 
conditioning and knockdown of promoted stress reactivity and 
anxiety-like behavior (Spadaro et al., 2015). Neurogenic 
commitment and neuronal survival, sustained overexpression of 
Miat promoted neuronal death (Aprea et al. 2013).   
HAND2-AS1 
(Dein) 
down Highly expressed in stage IVS neuroblastoma (Voth et al., 2007). 
Expression is neuroblastoma is coregulated together with HAND2 
(Voth et al., 2009). 
C6orf176 
(LINC00473) 
up A possible regulatory function in response to cAMP signalling 
(Reitmair et al., 2012).  
HOXD-AS1 up It is induced by RA, could be regulated via PI3K/Akt pathway and 
controls genes involved in RA signaling, angiogenesis and 
inflammation (Yarmishyn et al., 2014). 
Table 9. Differentially expressed lncRNAs that have been identified in literature (Aliperti and 
Donizetti, 2016). 
 
RP11-370A5.1 413 171 0.01 no 1.68 
AC084018.1 1220 348 0.06 no 1.68 
RAD51-AS1 718 105 0.004 no 1.67 
SOX9-AS1 394 132 0.05 no 1.66 
TTTY7 1367 180 0.01 no 1.65 
AC084018.1 1521 246 0.06 no 1.65 
AC046143.3 972 105 0.001 no 1.62 
H1FX-AS1 917 252 0.05 no 1.61 
CTC-444N24.8 1385 228 0.02 no 1.59 
RAD51-AS1 419 171 0.006 no 1.58 
RP11-182L21.2 3272 585 0.54 yes 1.58 
RP11-535A19.2 444 93 0.04 no 1.56 
ENST00000529707 1130 201 0.01 no 1.56 
ENST00000589496 5702 783 0.91 yes 1.55 
RP11-404P21.5 460 261 0.01 no 1.53 
RP11-217B1.2 1109 204 0.01 no 1.52 
LINC00324 2082 447 0.24 no 1.51 
CTB-55O6.12 686 216 0.10 no 1.51 
linc-RPL19-3 2365 255 0.01 no 1.50 
RP11-473I1.10 8334 273 0.005 no 1.43 
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These evidences supported the hypothesis of an involvement of lncRNAs in BDNF-mediated 
molecular effects. To assess the putative role of the differentially expressed lncRNAs, we 
examined the function of coding genes located near the lncRNAs in the genome. In fact, very 
often the expression of the lncRNAs affect cis regulation of nearby transcription. We first 
identified the neighbouring coding genes by using the GREAT tool 
(http://bejerano.stanford.edu/great/public/html/) (McLean et al., 2010), and then used this gene 
list together with the list of differentially expressed coding RNAs found in microarray survey 
analyse using the DAVID tool (http://david.abcc.ncifcrf.gov/) (Dennis et al., 2003). This tool 
outputs a wide range of information, including Gene Ontology (GO) and pathway enrichment, 
providing an overview of the functions and relationship of the differentially expressed genes. The 
most enriched biological processes are related to transcription regulation and RNA metabolic 
process, while there are also processes related to chromatin organization and function (Figure 11 
A). The involvement of genomic loci of lncRNAs in transcription control and chromatin structure 
was also revealed by GO in terms of molecular function and cellular component (Figures 11 B 
and C). This analysis corroborated the hypothesis that lncRNAs and coding genes identified in 
the early phase of BDNF stimulation may act in concert to regulate the gene expression of 
downstream genes at a transcriptional level. 
 
Fig 11. Gene Ontology (GO) enrichment analysis for lncRNAs by DAVID bioinformatics tool. (A) 
GO analysis of lncRNA-target genes + differentially expressed coding genes according to biological 
process. (B) GO analysis of lncRNA-target genes + differentially expressed coding genes according to 
molecular function. (C) GO analysis of lncRNA-target genes + differentially expressed coding genes 
according to cell component. (D) Top 10 biological processes for coding genes that are target of miRNA 
potentially regulated by the differentially expressed lncRNAs. Grouped GO terms are reported as following 
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with the ID of the single gene ontology term. transcription and gene expression: GO:0045449 + 
GO:0006350 + GO:0006355 + GO:0006357 + GO:0045893 +  + GO:0045941 +  GO:0010628 + 
GO:0045944; RNA methabolic process:  GO:0051252 +  GO:0051254 + GO:0045935 + GO:0051173 + 
GO:0010604;  biosynthetic process:  GO:0010557 + GO:0031328 + GO:0009891; macromolecular 
complex assembly and organization: GO:0065003 + GO:0043933 + GO:0034622 + GO:0034621; blood 
vessel and vasculatur development: GO:0001568 + GO:0001944; chromatin organization and function: 
GO:0006334 + GO:0031497 + GO:0065004 + GO:0034728 + GO:0006323 + GO:0006333; regulation of 
synaptic plasticity: GO:0048168 + GO:0048167; mesoderm morphogenesis and development: 
GO:0048332 + GO:0007498. The number on the pie chart indicates the number of differentially expressed 
coding genes associated to the GO term (or GO group), while the number in brackets indicates the number 
of genes located near the differentially expressed lncRNAs (Aliperti and Donizetti, 2016). 
 
The list of differentially expressed lncRNAs was submitted to the lncRNome database 
(http://genome.igib.res.in/lncRNome) (Bhartiya et al., 2013), that contains information about 
6,800 protein binding sites. These data were obtained from PAR-CLIP and CLIP-Seq analyses. 
The analysis returned a result for only a small percentage of the lncRNAs in question. In general, 
the presence of binding sites can be observed for a small group of proteins, such as PTB, PUM2, 
QKI, IGF2BP1, IGF2BP2, IGF2BP3, TNRC6A and TNRC6C (Table 10). 
Sequence Name Alternative gene name Proteins (lncRNome) 
ENST00000455853 LINC00473 (C6orf176) PTB 
ENST00000570843 RP11-473M20.16 PUM2, QKI, IGF2P1, IGF2BP2, 
IGF2BP3, TNRC6A, TNRC6C 
ENST00000549329 HOXD-AS1 IGF2BP2 
ENST00000544868 MALAT1 PTB, PUM2, QKI, IGF2BP1, 
IGF2BP2, IGF2BP3, TNRC6C 
ENST00000508832 MALAT1 PTB, PUM2, IGF2BP1, IGF2BP2, 
IGF2BP3, TNRC6C 
ENST00000511998 H1FX-AS1 IGF2BP1, IGF2BP2, IGF2BP3 
ENST00000569473 RP11-217B1.2 PUM2, QKI, IGF2BP1, IGF2BP2, 
IGF2BP3, TNRC6A, TNRC6B, 
TNRC6C 
ENST00000315707 LINC00324 PUM2, QKI, IGF2BP2, IGF2BP3, 
TNRC6A, TNRC6B, TNRC6C 
ENST00000574616 RP11-473I1.10 PTB, IGF2P1, IGF2BP2, IGF2P3 
Table 10. lncRNAs – proteins interaction. 
 
Many pieces of evidence demonstrated that lncRNAs may also influence gene expression at a 
post-transcriptional level. The effect is achieved by interfering with miRNAs pathways as 
competitive endogenous RNAs (ceRNAs). In this process, thanks to complementary sequences, 
the lncRNA interact with miRNA that in turn is no longer available to bind its target mRNA, thus 
reducing the repression of this mRNA. lnCeDB (http://gyanxet-beta.com/lncedb/) provides a 
database of human lncRNAs (from the GENCODE version 19) that can potentially act as 
ceRNAs. Using this database, we found a list of miRNAs, of which seven are associated with 
neuropathologies as reported in the mir2disease database (Table 11). To acquire information on 
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biological processes affected by the putative lncRNA-miRNA interaction, we retrieved a list of 
experimentally validated mRNA targets of all previously-identified miRNAs and performed a 
functional analysis with the DAVID tool. In the top 10 biological processes, the most represented 
categories are related to the regulation of transcription and RNA metabolic processes (Figure 11 
D).    
                                                miRNA symbol neuropathology 
                                                     hsa-miR-339-5p Neurodegeneration 
                                                       hsa-miR-433  Parkinson's disease 
                                                      hsa-miR-133b Parkinson's disease 
                                                      hsa-miR-346  Schizophrenia 
                                                      hsa-miR-328  Alzheimer's disease 
                                                      hsa-miR-299-3p Alzheimer's disease 
                                                      hsa-miR-422a  Multiple sclerosis 
 
Table 11. Putative miRNA targets on lncRNA and their involvement in neuropsychiatric diseases. 
(Aliperti and Donizetti, 2016). 
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PART II 
EGR1 in neuronal differentiation 
4.II.1 EGR1  
In the above analysis, we provided an overview of a number of coding and non-coding genes 
involved in the BDNF function during neuronal differentiation. Among the coding genes that we 
found regulated by neurotrophin, EGR1 is likely one of the most enigmatic concerning its role in 
neuronal differentiation. In fact, the function of EGR1 is particularly well-documented in the adult 
nervous system, where it acts as an activity-dependent transcription factor highly expressed in 
long-term potentiation (LTP) and long-term depression (LTD) and is often used as a marker of 
neuronal stimulation. Because of an apparent normal embryonic brain development in EGR1-KO 
mice and relatively few studies on its expression pattern in embryos (Watson and Milbrandt, 
1990), the involvement of EGR1 in neuronal development during embryogenesis remains elusive. 
In addition, one limitation in the use of in vivo models such as EGR1-KO mice is questionable, 
mainly because it is difficult to exclude the fact that other transcription factors related to EGR1 
(that is EGR2, EGR3, and EGR4) may compensate for the loss of function of this gene. Recently, 
a fluorescent transgene approach provided evidence of a wide distribution of Egr1+/Sox2+ cells, 
suggesting a general role for EGR1 in cellular regulation during late embryonic/early postnatal 
brain development (Wells et al., 2011). Beyond this sporadic evidence, the hypothesis of a 
function for EGR1 in neurons development is mainly supported by the use of rat/mouse neuronal 
cancer cell lines as progenitor-type models, based on their ability to differentiate after specific 
stimulations. In this regard, the discovery of EGR1 three decades ago was strictly related to its 
function in neuronal maturation (Milbrandt, 1987). In that seminal paper, Milbrandt (1987) 
described the identification of a cDNA clone for a transcript able to quickly respond to NGF 
stimulation in the rat pheochromocytoma PC12. NGF and other neurotrophic factors play an 
essential role in the regulation of the growth, survival, and differentiation of neurons. In this 
regard, the expression induction of EGR1 by different neurotrophic factors including BDNF, as 
reported in the present thesis in a human neuronal model, points out that this gene may play a key 
role in the transcriptional programs underlying survival and differentiation of neuronal cells. With 
the aim to explore the role of human EGR1 in neuronal maturation, we designed different 
molecular approaches to interfere with EGR1 gene function. One of the main strategies was based 
on the CRISPR-Cas9 technology to knockout the EGR1 gene in the human neuroblastoma cell 
line SH-SY5Y.  
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4.II.2 EGR1 expression level during RA-dependent differentiation 
We first sought to check if EGR1 is involved in the early phases of differentiation during RA 
treatment. Different reports demonstrated that RA stimulation can induce an increase of EGR1 
expression level in different cell cultures (Edwards et al., 1991; Larsen et al., 1994; Lee and Kim, 
2004).  In this regard, we evaluated the RA induction of the EGR1 gene in the N-enriched SH-
SY5Y model used in this thesis. As shown in the Figure 12 A, we did not find a RA-dependent 
increase of EGR1 transcript level in the early period after stimulation; a significant increase was 
observed after 24h and 48h of RA treatment with a corresponding increase in protein levels 
(Figures 12 A and B).  
 
Fig 12. EGR1 expression level during RA-treatment of N-enriched SH-SY5Y cells. (A) Transcript level 
changes examined by qPCR at the indicated time points. EGR1 gene expression level was normalized to 
the reference transcript GAPDH and calculated by the 2 – ΔΔCt method. The sample at time 0h was used as 
a calibrator. The results from independent biological replicates are expressed as mean of fold change ± 
SEM. Statistical analysis of the qPCR data was carried out using a two‐tailed t test. Significance of 
difference from time 0h (*p < 0.05) is shown. (B) EGR1 protein level analysed by Western Blot at the 
indicated time points. The level of GAPDH protein was used as a loading control. 
 
4.II.3 EGR1 knockout cell line generation and validation 
To functionally evaluate the role of EGR1 in human neuronal differentiation, we used the N-
enriched SH-SY5Y neuroblastoma cell line to generate a KO cell line for EGR1. The cells were 
transfected with the all-in-one plasmid pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene plasmid 
#62988), which includes both the coding region for the Cas9 and the coding sequence for the 
gRNA (Figure 13).  
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Fig 13. Basic elements of the CRISPR/Cas9 technology used to knockout the EGR1 gene. (A) 
Graphical representation of the pSpCas9 (BB) -2A-Pure (PX459) V2.0 vector used for the CRISPR-Cas9 
system (www.addgene.com). (B) Schematic representation of the EGR1 transcript and the corresponding 
DNA sequence recognized by the gRNA. The rectangles represented the two exons of EGR1 transcript with 
the black region representing the coding region. The ATG of the EGR1 gene is highlighted in red, while 
the arrow indicated the gRNA target sequence. 
 
After the puromycin selection of positive transfected clones, we isolated different single cell-
derived populations. The target genomic region of two of the selected populations was amplified 
by PCR and subcloned in a vector to obtain the sequence of both the alleles separately and to 
confirm the KO generation. One of these two KO lines was used for further validation and 
analysis. As reported in Figure 13 C, this KO line carried two different genomic mutations: one 
single nucleotide insertion for one allele, and one single nucleotide deletion for the second allele 
(Figure 14). 
 
Fig 14. Analysis of the EGR1 genomic sequence in the KO cell line. Electropherograms of both WT and 
KO EGR1 genomic sequence. 
 
In both cases, the INDEL (INsertion/DELetion) determined the generation of a premature stop 
codon because of a frame-shift mutation. To further validate the EGR1-KO cell line, we employed 
western blotting analysis to provide evidence for the lack of functional protein production. The 
analysis showed that the protein level strongly increased in WT cells after 24h and 48h of RA 
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stimulation, while the corresponding protein was completely absent in KO cells (Figure 15). At 
that point, we wanted to further validate the EGR1-KO cell line and provide evidence that the 
loss of EGR1 protein production depended on the premature stop codon, generated by the genome 
editing strategy and not by misregulatation of transcript expression. The qPCR analysis of the 
EGR1-KO cell line showed that RA stimulation is still able to increase the transcript level after 
24h and 48h of treatment, demonstrating that the EGR1 transcript regulation and the upstream 
activating pathways were functional in the KO cell line (data not shown). 
 
Fig 15. Validation of the EGR1 KO cell line by qPCR and western blotting analysis. EGR1 protein level analysed 
by Western Blot at the indicated time points in WT and KO cells. The level of GAPDH protein was used as a loading 
control. 
 
4.II.4 KO cells are unable to properly differentiate under RA stimulation 
To test whether the knockout of the EGR1 gene affected the RA-induced differentiation process, 
we followed the morphological changes after RA treatment by microscopy observation. EGR1-
WT cells differentiated normally under 10µM RA stimulation, as evidenced by changes in the 
shape of soma and neurites elongation and branching (Figure 16). In contrast, EGR1-KO cells did 
not show any differentiation landmarks and underwent cell shrinkage and detachment (Figure 16). 
 
Fig 16. Effect of RA-induced differentiation on WT and KO cells. Time (0) represented starved cells 
before RA treatment at 10µM concentration. (d): days of RA treatment. 
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Interestingly, this effect was also confirmed with smaller concentrations (3 and 6 µM) of RA 
(Figure 17), demonstrating that EGR1 is required for a correct RA-induced differentiation. 
 
Fig 17. Effect of RA-induced differentiation on EGR1 WT and KO cells. Cells treated with RA at 
different concentrations for 6 days. CTRL represented cells grown in the presence of only DMSO. 
 
4.II.5 Effects of EGR1-KO on the RA pathway 
These results prompted us to investigate if the inability to differentiate under RA treatment 
depends on the misregulation of RA signalling. To make this determination, we analysed the 
expression levels of genes involved in the RA pathway including retinoic receptors (RARα, RARβ, 
and RARγ) and CYP26a1, a key component of RA metabolic inactivation. As shown in Figure 18, 
the expression level of all analysed genes increased after 2 days of morphogen treatment in EGR1-
WT cells. Differently, RARγ showed a higher increase in EGR1-KO cells compared to WT cells 
and, worthy to note, CYP26a1 showed an extremely lowered increased expression after 1 and 2 
days of RA in KO than WT cells (Figure 18), corroborating the idea that KO cells are affected in 
the RA signalling pathway.  
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Fig 18. Expression pattern comparison of RA signalling genes in EGR1 WT and KO cells. Expression 
level change in EGR1 WT and KO cells after RA stimulation at the indicated time points for CYP26a1, 
RARα, RARβ and RARγ. Gene expression level was normalized to the reference transcript GAPDH and 
calculated by the 2 – ΔΔCt method. The sample at time 0 was used as a calibrator. The results from 
independent biological replicates are expressed as mean of fold change ± SEM. Statistical analysis of the 
qPCR data was carried out using a two‐tailed t test. Significance of difference (*p < 0.05) is shown. 
 
4.II.6 Dysregulation of BDNF system in EGR1-KO cells 
During RA stimulation, SH-SY5Y normally increases the expression level of NTRK2, leading to 
the idea that RA may also affect the expression of BDNF and its receptors during differentiation.  
In this regard, we investigated mRNA expression level changes of BDNF, the high-affinity 
receptor NTRK2 and the low-affinity NGFR (also known as p75). The transcript level of BDNF 
slightly increased after 2 days of RA treatment in both WT and KO cells, while a different pattern 
was observed for the receptors (Figure 19). The mRNA for the high-affinity NTRK2 receptor 
progressively increased during RA treatment in WT cells, while a smaller increase was observed 
in KO after 1 and 2 days of RA treatment (Figure 19). Regarding the NGFR receptor, we observed 
no significant changes in the mRNA level after RA treatment in WT cells, and a large increase in 
KO cells at 1 and 2 days (Figure 19). These observations suggested that the effect of knockout of 
EGR1 in RA-induced differentiation may also involve BDNF signalling. 
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Fig 19. Expression pattern comparison of BDNF signalling genes in EGR1 WT and KO cells. 
Expression level change in EGR1 WT and KO cells after RA stimulation at the indicated time points for 
BDNF (A), NTRK2 (B), and NGFR (C). Gene expression level was normalized to the reference transcript 
GAPDH and calculated by the 2 – ΔΔCt method. The sample at time 0h was used as a calibrator. The results 
from independent biological replicates are expressed as mean of fold change ± SEM. Statistical analysis of 
the qPCR data was carried out using a two‐tailed t test. Significance of difference from time 0h 
 (*p < 0.05) is shown. 
 
4.II.7 Effect of TPA stimulation on EGR1-KO differentiation 
The effect of RA treatment on EGR1-KO highlighted that this transcription factor may be 
involved in the correct differentiation following RA stimulation. To further investigate the 
relevance of EGR1 in neuronal differentiation, we wanted to broaden the analysis by using a 
different stimulating agent. As such, we employed TPA (12-O-tetradecanoyl-phorbol-13-acetate), 
another well-known differentiating agent that promotes cell proliferation arrest and induces 
differentiation of the human neuroblastoma SH-SY5Y cell line (Encinas et al., 2000). In this 
preliminary investigation, we compared the effect of TPA and RA using DMSO as a control. The 
microscopy analysis showed that cells stimulated with TPA or RA did not undergo a 
differentiation process and progressively led to cell death (Figure 20), demonstrating that EGR1-
KO cells were unable to independently differentiate the stimulating agent used. 
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Fig 20. Effect of RA- and TPA-induced differentiation on KO cells. CTRL represented cells grown in 
the presence of only DMSO. 
 
4.II.8 EGR1 knockout in iPSCs 
The induced pluripotent stem cell (iPSC) technology has revolutionized many fields, in particular 
the study of the development and modelling of disease and cell therapy. Somatic cells can be 
reprogrammed in a pluripotent stem cell state, similar to the state present in very early 
embryogenesis through the transient expression of four transcription factors (Oct4, Sox2, Klf4 
and c-Myc) (Takahashi and Yamanaka, 2006; Takahashi et al., 2007). 
It is important to emphasize that such cells are diploid and karyotypically normal. They can self-
renew for many cell divisions and can be differentiated into a wide range of different cell types. 
These characteristics lend themselves to the study of cell development and function in both 
normal and pathological states. In fact, since cells are reprogrammed at a very early stage of 
development, they can be used to monitor both developmental or differentiation defects, and the 
temporal sequence of events in the early stages of disease progression (Bassett, 2017). 
The neuronal cells produced by iPSCs closely recapitulate the progression from early 
embryogenesis to late fetal periods in vitro and produce neuronal cells at various stages of 
maturity. These advantages make iPSCs a versatile tool for exploring early molecular and cellular 
phenotypes. In regard to the functional study of the transcription factor EGR1 in neuronal 
development in a more physiological system, it was interesting to try to extend the results obtained 
in the tumor cell line in the iPSCs. I spent 3 months in the laboratory of Dr. Michael Ziller at Max 
Planck Institute of Psychiatry (Munich) working with the HDF6 cell line. I transfected cells with 
the same vector used in SH-SY5Y cells. After the puromycin selection of positive transfected 
cells, I isolated different single clones and amplified the target genomic region by PCR. 
Unfortunately, none of the examined clones showed any mutation in the nucleotide sequence. It 
will therefore be necessary to make changes in the transfection protocol in order to increase 
editing efficiency. 
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4.II.9 Identification of a new alternative splicing isoform for EGR1  
Among the strategies to investigate EGR1 involvement in human neuronal differentiation, we 
planned to generate and use an expression vector for this transcription factor. This approach was 
designed to test the effects of EGR1 iper-expression in WT cells and to perform rescue 
experiments in KO cells. To clone the entire EGR1 coding region, we designed a pair of primers 
spanning the start codon to the stop codon to use in PCR reactions. As a template, we used cDNA 
samples obtained by the retrotranscription of RNA extracted from N-type SH-SY5Y cells treated 
with RA for 6 days. As shown in the Figure 21, we surprisingly found two different amplicons: 
one of the expected size and an additional shorter one (Figure 21 A). We isolated and cloned both 
the PCR products to identify the corresponding sequences. As expected, the amplicon with the 
highest molecular weight corresponded to the entire coding sequence of EGR1 reported in the 
genome databases; surprisingly, the shorter amplicon corresponded to the EGR1 transcript 
characterized by a deletion of 414 nucleotides in length in the coding region (Figure 21 B). The 
bioinformatic translation of the alternative EGR1 isoform showed that it retained the correct frame 
and encoded for a shorter protein compared to the canonical EGR1 (Figure 21 C). This alternative 
isoform lacks a protein region of 138 amino acids in length from the aa 141 to the aa 278.  
 
Fig 21. Identification of the EGR1 splicing isoform. (A) Electrophoretic run of the PCR products related 
to EGR1 CDS amplification. Lane 1: 1kb marker. Lane 2: PCR reaction for EGR1 CDS. (B) Schematic 
representation of the two EGR1 transcript isoforms. The rectangles represented the two exons of EGR1 
transcript with the black region representing the coding region. The alternative splicing was indicated by 
dashed green lines. (C) Amino acid sequence of the EGR1 protein. Underlined amino acid region 
represented the sequence missing in the putative alternative EGR1 isoform. 
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To provide a preliminary investigation of the relevance of this splicing isoform in neuronal 
differentiation, we analysed its expression pattern both downstream to BDNF and RA stimulation. 
To do so, we performed qPCR analysis by using specific primers designed to differentiate the two 
isoforms (see the Materials and Methods section for details). As shown in Figure 22, the transcript 
level of the isoform was unaffected during early RA treatment, while it increased after 24h and 
48h of treatment in a manner similar to the canonical isoform (Figure 22 A). Regarding the 
expression pattern under BDNF stimulation, we performed the transcript level analysis at 
different time points. As shown in the Figure 22, the transcript level variation of the canonical 
EGR1 isoform followed the typical kinetics of the immediate early genes, with a rapid increase 
until it reached a peak after 1h of stimulation followed by a rapid decrease (Figure 22 B.). The 
fold change of the splicing isoform at each point in time corresponded to that of the canonical 
isoform (Figure 22 B.). Both the expression pattern after RA and BDNF stimulation demonstrated 
that the alternative isoform may be involved in the EGR1 function during neuronal differentiation. 
 
Fig 22. Expression pattern comparison of EGR1 splicing isoforms under RA and BDNF stimulation. 
Expression level change in N-enriched SH-SY5Y cells after RA (A) and BDNF (B) stimulation at the 
indicated time points for the canonical EGR1 (grey line) and the splicing isoform Δ141-278 (dashed red 
line). Time (0h) represented cells before RA treatment (A) or after 6 days of RA-induced differentiation 
(B). Gene expression level was normalized to the reference gene (GAPDH) and calculated by the 2 – ΔΔCt 
method. The sample at time 0h was used as a calibrator. The results from independent biological replicates 
are expressed as mean of fold change ± SEM. Statistical analysis of the qPCR data was carried out using a 
two‐tailed t test. Significance of difference from time 0h (*p < 0.05) is shown. 
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To gain preliminary insights into the molecular mechanism of action of the alternative EGR1 
isoform, we analysed the cellular localization of this protein. To do so, we transfected expression 
vectors for both the canonical and alternative EGR1 isoform in HEK293T cells. Western blotting 
experiments on nuclear and cytoplasmic fraction showed that the EGR1 alternative isoform 
preferentially had nuclear localization (Figure 23 A), as also confirmed by immunofluorescence 
analysis (Figure 23 B). This result led us to hypothesize that the alternative EGR1 isoform may 
affect gene transcription. 
 
Fig 23. Cellular localization of EGR1 Δ141-278 splicing isoform. (A) Analysis of EGR1 localization by 
Western-blot. HEK293T cells transfected with both EGR1 constructs and empty plasmid were subjected to 
cellular fractionation. Distribution of canonical and Δ141-278 EGR1 isoforms was analysed in cytosolic 
(C) and nuclear (N) fractions. GADPH and histone H3 were respectively used as specific markers of the 
cytoplasmic and the nuclear fractions. (B) Localization of EGR1 in HEK293T cells transfected with empty 
plasmid, canonical and Δ141-278 EGR1 isoforms. Representative images of localization of EGR1 isoforms 
using anti-EGR1 antibody (red). The localization of nucleus was determined by immunofluorescence with 
4 ,6-Diamidine-2-phenylindole dihydrochloride (DAPI). TUBB3 immunolocalization (green) was used as 
a marker of cytoplasmic distribution. 
 
To evaluate this hypothesis, we analysed the expression level variation of different EGR1 target 
genes. We planned iper-expression experiments for both the canonical and alternative isoform 
and qPCR assays on putative target genes. After a preliminary survey to identify good candidate 
genes able to respond to EGR1 regulation, we selected two genes, ARC and SIK1. As shown in 
Figure 24 B, for both genes only the canonical EGR1 isoform was able to increase transcription, 
demonstrating that the alternative isoform lacks the ability to activate transcription. In addition, 
the co-transfection experiment demonstrated that the canonical EGR1-dependent increase of ARC 
transcript is lowed by the present of Δ141-278 (Figure 24 B). 
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Fig 24. Expression pattern comparison in EGR1 and EGR1 Δ141-278 iper-expressing cells. (A) 
Analysis of the isoforms iper-expression in HEK293T cells transfected with both EGR1 constructs and 
empty plasmid by Western Blot. The level of GAPDH protein was used as a loading control. (B) Expression level 
change for ARC and SIK1 transcripts in EGR1 and EGR1 Δ141-278 iper-expressing cells. Gene expression 
level was normalized to the reference transcript GAPDH and calculated by the 2 – ΔΔCt method. The sample 
transfected with vector was used as a calibrator. The results from independent biological replicates are 
expressed as mean of fold change ± SEM. Statistical analysis of the qPCR data was carried out using a two‐
tailed t test. Significance of difference in fold change (*p < 0.05) is shown. 
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PART III 
Preliminary characterization of LINC00473 (C6orf176) 
4.III.1 LINC00473 overview 
The LINC00473 gene has 5 different alternative splicing isoforms (Figure 25).  
 
Fig 25. Schematic representation of the 5 different isoforms of the LINC00473 gene. 
 
The microarray platform used for the analysis discussed in Part I contained probes for all the 
LINC00473 splicing isoforms. The microarray analysis results showed that only the LINC00473-
202 isoform increased the expression level after BDNF stimulation. Interestingly, the analysis of 
coding potential by the CPAT software argued the possibility that this isoform might encode for 
a relatively short protein (Table 12). The CPAT analysis was also extended to the other splicing 
isoforms of the LINC00473 gene, demonstrating that only the LINC00473-202 isoform had a 
significant coding potential probability (Table 12).  
 
Sequence 
Name 
RNA 
Size 
ORF 
Size 
Coding 
Probability 
Coding 
Label 
LINC00473-201 798 321 0.024 no 
LINC00473-202 1822 561 0.478 yes 
LINC00473-203 929 321 0.024 no 
LINC00473-204 1717 321 0.023 no 
LINC00473-205 2212 321 0.022 no 
Table 12. Results of CPAT analysis for LINC00473 isoforms. 
 
This result led us to evaluate the evolutionary conservation of the putative encoded protein of the 
LINC00472-202 isoform. We performed a TBLASTN search of the NCBI nucleotide database 
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using the putative amino acid sequence of the LINC00473-202 isoform as bait. We found many 
sequences with high alignment scores; all of these sequences resulted as predicted by automated 
computational analysis from a genomic sequence and belonged to primate species (Figure 26). 
The amino acid alignment showed that the sequences can be subdivided in two groups: one that 
include a human sequence and is characterized by a putative protein length of 186 aa (185 for Pan 
paniscus and Pan troglodytes), and a second characterized by a putative longer protein containing 
an additional N-terminal region (Figure 26). 
 
Fig 26. Amino acid alignment of the LINC00473 putative encoded protein. Homo sapiens (A8K010), 
Gorilla gorilla (XP_018885655.1), Pan paniscus (XP_008971877.1), Pan troglodytes (XP_016812094.1), 
Rhinopithecus bieti (XP_017725042.1), Piliocolobus tephrosceles (XP_023079412.1), Colobus angolensis 
palliates (XP_011790480.1), Papio Anubis (XP_009204634.2), Cercocebus atys (XP_011933425.1), 
Chlorocebus sabaeus (XP_008005965.1), Macaca fascicularis (XP_015303993.1), Macaca nemestrina 
(XP_011749299.1). “*” indicates positions which have a single, fully conserved residue; “:” indicates 
conservation between groups of strongly similar properties; “.” indicates conservation between groups of 
weakly similar properties. 
 
4.III.2 LINC00473 expression levels under RA and BDNF stimulation 
The identification of the LINC00473-202 expression under BDNF stimulation shows that this 
gene may play a role in the differentiation process. In this regard, as performed for the EGR1 gene 
in the Part II, we extended the analysis of the expression level during RA-induced differentiation. 
The qPCR analysis showed that although the RA is able to induce a transcript level variation of 
this gene, this change was not significant, likely reflecting an overall very low expression level 
(Cycle threshold Ct ranging from 27 to 30).  
In contrast, under BDNF stimulation the overall transcript level was higher compared to RA 
stimulation. In particular, we evaluated the LINC00473-202 expression after different time points 
of BDNF stimulation. As shown in Figure 27, the transcript level increased starting from 1h and 
reached a peak after 2h of BDNF treatment and then decreased at 4h, with kinetics resembling 
those of the immediate early genes. Interestingly, the expression pattern comparison of the EGR1 
and LINC00473 genes after BDNF stimulation showed that the expression of EGR1 anticipated 
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that of LINC00473 (Figure 27). This data led us to hypothesize that EGR1 could be involved in 
the transcription of the LINC00473 gene.  
 
Fig 27. Expression pattern comparison of EGR1 and LINC00473 under BDNF stimulation. Expression level 
change in N-enriched SH-SY5Y cells after BDNF stimulation at the indicated time points for the canonical EGR1 
(black line) and LINC00473 (dashed grey line). Time (0h) represented cells after 6 days of RA-induced 
differentiation. Gene expression level was normalized to the reference gene (GAPDH) and calculated by the              
2 – ΔΔCt method. The sample at time 0h was used as a calibrator. The results from independent biological replicates 
are expressed as mean of fold change ± SEM. Statistical analysis of the qPCR data was carried out using a two‐
tailed t test. Significance of difference from time 0h (*p < 0.05) is shown. 
 
4.III.3 LINC00473 expression levels under FBS stimulation 
In order to test whether LINC00473-202, as IEG, also varies in response to stimulation with FBS, 
we evaluated LINC00473-202 expression after different time points of FBS stimulation. The 
transcript level increased starting from 1h and reached a peak after 2h of serum stimulation and 
then decreased at 4h, with kinetics resembling those of the immediate early genes (Figure 28). 
Furthermore, once again, the expression of EGR1 anticipated that of LINC00473 (Figure 28). 
 
Fig 28. Expression pattern comparison of EGR1 and LINC00473 under FBS stimulation. Expression level 
change in HEK293T cells after serum stimulation at the indicated time points for the canonical EGR1 (black line) 
and LINC00473 (dashed grey line). Time (0h) represented cells before FBS treatment. Gene expression level was 
normalized to the reference gene (GAPDH) and calculated by the 2 – ΔΔCt method. The sample at time 0h was used 
as a calibrator. The results from independent biological replicates are expressed as mean of fold change ± SEM. 
Statistical analysis of the qPCR data was carried out using a two‐tailed t test. Significance of difference from time 
0h (*p < 0.05) is shown. 
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The putative regulation of LINC00473 by EGR1 is corroborated by the analysis of the EGR1 
binding site reported in the Ensembl database (https://www.ensembl.org/index.html) (Figure 29). 
In particular, Chip-seq results in H1ESC cells (human embryonic stem cells) demonstrated EGR1 
binding at the level of the promoter region of the LINC00473 gene (Figure 29). 
 
Fig 29. Graphical representation of the binding site for EGR1 in the LINC00473 promoter as 
reported in the genome browser Ensembl (https://www.ensembl.org/index.html). 
 
4.III.4 LINC00473 KO 
In order to obtain preliminary insights into the function of the LINC00473 gene, we designed KO 
experiments by using CRISPR/Cas9 technology in HEK293T cells. The strategy was based on 
the use of an all-in-one vector AIO-PURO (Addgene plasmid #74630) with the Cas9 Nickase. 
This enzyme variant is able to generate a single-stranded break instead of a double-strand break, 
and when used with two adjacent gRNAs, it can lower the probability of off-target editing. In 
particular the gRNAs were design to remove a region inside the ORF of the putative encoding 
LINC00473-202 isoform (Figure 30).  
 
Fig 30. Basic elements of the CRISPR/Cas9 technology used to knockout the LINC00473 gene. (A) 
Graphical representation of the AIO-PURO vector used for the CRISPR-Cas9 system (www.addgene.com). 
(B) Schematic representation of the LINC00473-202 transcript and the corresponding DNA sequence 
recognized by the gRNAs. The rectangles represented the two exons of LINC00473-202. The ATG of the 
LINC00473 gene is highlighted in green; the STOP codon of the LINC00473 gene is highlighted in red. 
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This approach allowed us to obtain deletion mutants as follows. Once gRNAs were cloned into 
the vector, we performed transfection experiments followed by antibiotic selection as reported in 
Materials and Methods section. By serial dilution of transfected cells, we obtained several single-
cell derived populations to be genetically analysed for the mutation. We amplified the genomic 
region related to the putative mutation by using primers spanning the interested region. As shown 
in Figure 31 A, PCR products showed a generation of several mutant populations, two of which 
were homozygous for the deletion. One of these two population was also confirmed for the 
deletion mutation by sequencing and was used for the following analysis (Figure 31 B).  
 
Fig 31. Analysis of the LINC00473 genomic sequence in the KO cell line. (A) Electrophoretic run of the 
PCR products related to LINC00473 amplification. Lane 1: WT. Lane 2: pool of KO populations. Lanes 
3,4,5,6,8,9,11: heterozygous KO populations. Lanes 7,10: homozygous KO populations. (B) Genomic 
sequence of LINC00473. Underlined nucleotide region represented the sequence missing in the KO cell 
line. The ATG of the LINC00473 gene is highlighted in green; the STOP codon of the LINC00473 gene is 
highlighted in red. 
 
As a preliminary investigation, we tested whether the knockout line for the LINC00473 gene 
affected the regulation of other IEGs. As shown in Figure 32, the KO affected the level of the 
transcript variation of the ARC and SIK1 gene but not of EGR1. These results suggested that the 
LINC00473 gene could therefore be involved in gene expression regulation of some IEGs. 
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Fig 32. Expression analysis for 3 immediate early genes after FBS stimulation in LINC00473 WT and 
KO cells. Expression level change in LINC00473 WT and KO cells after serum stimulation at the indicated 
time points for the canonical EGR1 (A), ARC (B), and SIK1 (C). Time (0h) represented cells before FBS 
treatment. Gene expression level was normalized to the reference gene (GAPDH) and calculated by the 2 – 
ΔΔCt method. The sample at time 0h was used as a calibrator. The results from independent biological 
replicates are expressed as mean of fold change ± SEM. Statistical analysis of the qPCR data was carried 
out using a two‐tailed t test. Significance of difference from time 0h (*p < 0.05) is shown. 
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5. DISCUSSION 
Neuronal differentiation is characterized by diverse cellular events including cell cycle exit, the 
acquisition of specialized structures and functions, and survival of those neurons that have been 
able to establish correct and functional synapses during development. While many transcription 
factors involved in the regulation and coordination of these events have been characterized, many 
others remain to be explored. Very recently, long non-coding RNA emerged as another important 
element of gene expression regulation with an essential role in cellular differentiation. Long non-
coding RNAs are a heterogeneous group of RNAs, many of which have emerged as regulators of 
genomic expression and stability. lncRNAs can influence gene expression through a wide variety 
of mechanisms, including transcriptional, post-transcriptional, and epigenetic regulation. The 
majority of lncRNAs are localized in the nucleus, where they can act as scaffolds for chromatin 
modifiers by interacting with chromatin-modifying complexes or as transcriptional co-regulators 
by binding to transcription factors (Rinn and Chang, 2012; Ulitsky and Bartel, 2013; Quan et al., 
2017). Instead, cytoplasmic lncRNAs act as modulators on post-transcriptional regulation of 
genes through various mechanisms during RNA processing, such as mRNA editing, alternative 
splicing and others (Quan et al., 2017). Recently, lncRNAs have received widespread attention as 
a potentially new and crucial layer of gene expression regulation. lncRNAs of all kinds have been 
implicated in a range of developmental processes and diseases and remarkably, 40% of the 
annotated lncRNAs are specifically expressed in the brain (Derrien et al., 2012). Many 
transcriptome analyses have revealed that lncRNAs are differentially expressed over time in brain 
regions. They can therefore have different functions in neuronal development and activity (Wu et 
al., 2013). It has been shown that lncRNAs play indispensable roles in the development of CNS 
from neural early differentiation to late synaptogenesis (Briggs et al., 2015; Quan et al., 2017). 
An example is BDNF-AS, which represses the expression of BDNF, reducing neuronal 
outgrowth, differentiation, survival and proliferation both in vitro and in vivo (Modarresi et al., 
2012). Knowledge of the mechanisms by which they act is still surprisingly in its infancy. The 
identification and characterization of coding and non-coding RNAs and their functional 
relationship is mandatory for unravelling the complex transcriptional programs underlying 
neuronal differentiation. In this regard, to preliminary address this item in a relatively easy model 
system of in vitro human neuronal differentiation, we employed SH-SY5Y, one of the most 
popular cell lines of human neuroblastoma in the neuroscience field (Pahlman et al., 1995; 
Kovalevich and Langford, 2013; Teppola et al., 2016). In fact, neuroblastoma cells can be induced 
to undergo neuronal differentiation by serum deprivation (Seeds et al., 1970), nerve growth factor 
(Jensen et al., 1988), or retinoic acid (RA) (Sidell et al., 1982). In the undifferentiated form, SH-
SY5Y cells continuously proliferate, express immature neuronal markers, and are characterized 
morphologically by neuroblast-like, non-polarized cell bodies with few and truncated processes. 
Following treatment with differentiation-inducing agents, SH-SY5Y cells decrease in 
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proliferation rate, exit from the cell cycle, and become morphologically more similar to primary 
neurons with long processes (Kovalevich and Langford, 2013). RA-induced neuronal 
differentiation of SH-SY5Y cells is a well-established model for molecular investigation of 
neuronal differentiation. This treatment is associated with inhibition of proliferation and extension 
of neurites (Preis et al., 1988; Toselli et al., 1996; Encinas et al., 2000; Stio et al., 2001; Cheung 
et al., 2009; Kovalevick and Langford, 2013; Teppola et al., 2016). The sequential exposure of 
SH-SY5Y cells to RA and the neurotrophin BDNF increases the maturation process, highlighting 
an essential role for BDNF in neuronal differentiation (Encinas et al., 2000).   
Brain-Derived Neurotrophic Factor (BDNF) has a key function in both neuronal development and 
the adult nervous system. The activity of BDNF affects many cellular processes in the nervous 
system including survival, growth, differentiation, synaptic plasticity of neurons, and long-term 
potentiation (LTP) (Casaccia-Bonnefil et al., 1999; Bibel and Barde, 2000; Xu et al., 2000; Huang 
and Reichardt, 2003; Bramham and Messaoudi, 2005; Gottmann et al., 2009; Minichiello, 2009; 
Park and Poo, 2013; Suliman et al., 2013; Mizui et al., 2014; Zagrebelsky and Korte, 2014; Leal 
et al., 2015). Knockout mice for BDNF usually die soon after birth and suffer developmental 
defects in the brain and sensory nervous system (Ernfors et al., 1995). Suppression of BDNF 
expression results in defective LTP and memory formation (Korte et al., 1995; Linnarsson et al., 
1997; Ma et al., 1997; Mu et al., 1999). In contrast, treatment of hippocampal slices from BDNF 
knockout mice with recombinant BDNF completely reversed deficits in long-term potentiation 
and significantly improved deficits in basal synaptic transmission (Patterson et al., 1996). The 
fundamental role of BDNF for the central nervous system is also highlighted by its dysregulation 
in both neurological and psychiatric disorders disorders (Binder and Scharfman, 2004; Pruunsild 
et al., 2007; Nagahara and Tuszynski, 2011; Weissmiller and Wu, 2012). In addition to its major 
roles in supporting neuronal survival and function during development and in adulthood, BDNF 
exerts potent pro-survival and functional effects in models of neurological disease (Nagahara and 
Tuszynski, 2011). The effects of BDNF on synaptogenesis, synaptic plasticity, and cell survival 
have been characterized mainly at the post-transcriptional level (Leal et al., 2015), while little is 
known about the genes regulated by the neurotrophin. The necessity of BDNF for correct neuronal 
development is also evident for the differentiation paradigm of SH-SY5Y cells, where the 
addition of BDNF after 4-6 days of RA treatment ensures the production of a cell population with 
significantly more characteristics of mature neurons compared to RA treatment alone, with 
obvious morphological changes, including intricate and complex neurite structure (Encinas et al., 
2000; Goldie et al., 2014). In the present thesis, we demonstrated that BDNF is able to involve 
several IEGs, belonging to both coding and non-coding genes, highlighting that the neurotrophin 
affects neuronal differentiation and survival by a plethora of mechanisms including gene 
transcription. In addition, our data are in agreement with a growing body of evidence in literature 
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on the role of lncRNAs in neuronal development (Lin et al., 2011; Roberts et al., 2014; D’haene 
et al., 2016; Quan et al., 2017).  
Regarding the biological function of the BDNF-regulated lncRNAs, we provided evidence that 
they can affect the regulation of genes involved in gene transcription, highlighting the putative 
role of lncRNAs in orchestrating the immediate response to BDNF. The analysis of lncRNA-
protein interaction in this thesis shows that these lncRNAs can influence different molecular 
processes including splicing. Genome-wide transcriptome analysis has revealed an exceptionally 
high level of alternative splicing in the mammalian brain (Yeo et al., 2004; Su et al., 2018). 
Alternative splicing is essential for cell differentiation, morphogenesis, the formation of complex 
neural networks and the regulation of synaptogenesis and plasticity (Norris and Calarco, 2012; 
Zheng and Black, 2013). Splicing regulation involves some specific neuron splicing factors and 
their interaction with ubiquitous factors (Raj and Blencowe, 2015; Vuong et al., 2016; Su et al., 
2018). For example, among the proteins identified in our analysis, there were PTB proteins that 
are important for the stem cell-to neuron transition (Boutz et al., 2007; Vuong et al., 2016; Su et 
al., 2018). In particular, PTBP1 suppresses the splicing of a subset of neural targets to inhibit 
neuronal differentiation, while PTBP2 expression is elevated in differentiating neuronal cells and 
activates certain neural targets that promote differentiation (Boutz et al., 2007; Su et al., 2018). 
Other proteins implicated in the lncRNA-protein interaction coordinate the export, trafficking, 
and precise localization and translation of RNA in cells during embryonic development and in 
adults, suggesting their different physiological duties. Among them, we identified IGF2BP 
proteins, which belong to a large family of RBPs that exhibit different expression patterns during 
development (Cao et al., 2018). In particular, IGF2BP2 regulates the differentiation of neural 
precursor cells into mature neurons or glial cells. Its levels are very high in embryonic 
development and then decrease as development progresses (Cao et al., 2018). Another example 
is PUM2 (Pumilio RNA-Binding Family Member 2) that acts as a translational repressor during 
embryonic development and cell differentiation. In immature neurons, loss of Pum2 led to 
enhanced dendritic outgrowth and arborization. In mature neurons, Pum2 down-regulation 
resulted in a significant reduction in dendritic spines and an increase in elongated dendritic 
filopodia (Vessey et al., 2010). 
The results obtained in this thesis work show that BDNF-regulated lncRNAs might also influence 
gene expression regulation through their interaction with miRNAs, a well-known class of 
ncRNAs highly expressed in the brain, in a spatially and temporally controlled manner (Fineberg 
et al., 2009). In particular, lncRNAs can affect gene expression by interfering with miRNAs 
pathways and acting as competing endogenous RNAs. Many miRNAs have been shown to be 
neuronal specific and involved in the control of neuronal differentiation, excitability and 
functions. Interestingly, aberrant expression and dysfunction of miRNAs have been associated 
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with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's. 
Overall, the analysis reported in Part I of this thesis gave an overview of the complex interplay 
between coding and non-coding RNA involved in the molecular mechanisms underlying gene 
expression regulation in the initial phase of BDNF-induced molecular cascade that affects 
neuronal differentiation.  
Among the genes that we identified as induced under BDNF stimulation, EGR1 is one of the most 
enigmatic. It is highly expressed in the brain where it acts as a pleiotropic mediator whose 
encoding gene is a convergence point for many signaling cascades (Raf/MEK/ERK, 
Rho/ROCK/LIMK, FHL, cAMP/PKA and PKC). Upon induction, it contributes to several cell 
behaviours including proliferation, apoptosis, and differentiation in a cell type- and stimulus-
specific manner (Thiel and Cibelli 2002; Pagel and Deindl, 2011). The role of EGR1 is 
particularly well-documented in the adult nervous system, where it plays important roles in 
learning and memory through regulation of genes that contribute to synaptic plasticity and long-
term potentiation and is often used as a marker of neuronal stimulation. Moreover, it is considered 
to be involved in pathological states such as addiction, anxiety, and neuropsychiatric disorders 
(Knapska and Kaczmarek 2004; Penke et al., 2013; Veyrac 2014; Duclot 2017). The important 
roles of EGR1 in neuron function (supported by studies on KO mice) include impaired long‐term 
memory in both spatial and non‐spatial learning tasks (Wei et al., 2000; Jones et al., 2001), altered 
behavioural responses to persistent inflammatory pain, and impaired contextual extinction 
learning and normal fear acquisition relative to wild-type controls (Han, 2014). The involvement 
of EGR1 in neuronal development during embryogenesis has not yet been unravelled. In fact, 
EGR1-KO mice showed apparently normal embryonic brain development and relatively few 
studies on its expression pattern in embryos have been produced (Watson and Milbrandt, 1990). 
The hypothesis of an EGR1 function in neuron development is mainly supported by different 
studies employing neuronal cancer cell lines as progenitor-type models, based on their ability to 
differentiate after specific stimulations. In this regard, the discovery of EGR1 three decades ago 
was strictly related to its function in neuronal maturation. In that seminal paper, Milbrandt (1987) 
described the identification of a cDNA clone for a transcript able to quickly respond to NGF 
stimulation in the rat pheochromocytoma PC12 and established different important characteristics 
of EGR1: the nature of the encoded protein as a zinc finger transcription factor, typical features 
of immediate early genes such as the rapid and transient induction of the expression and its 
independence from de novo protein synthesis, and the involvement in neuronal differentiation as 
a neurotrophin-responsive gene. Neurotrophic factors play an essential role in the regulation of 
the growth, survival, and differentiation of neurons and astrocytes in the central and peripheral 
nervous system both during embryonic development and in adulthood (Oliveira et al., 2012; Vilar 
and Mira, 2016; Kashyap et., 2018). In this regard, the expression induction of EGR1 by different 
neurotrophic factors including NGF, GDNF (Milbrandt, 1987; Hu and Russek 2008; 
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Ahmadiantehrani and Ron 2013), and BDNF, as shown in the present thesis (Aliperti and 
Donizetti, 2016), point out that this gene might be a key element in the transcriptional programs 
underlying survival and differentiation of neuronal cells. The fundamental role of EGR1 in 
neuronal differentiation was corroborated by the results of the present thesis, where we took 
advantage of the generation of a KO cell line for EGR1 in the SH-SY5Y cell line. We showed 
that the EGR1-KO line was unable to differentiate under RA stimulation and in fact underwent 
cell death. The analysis of the gene expression levels of key elements of the RA pathway, 
including retinoic receptors (RARα, RARβ, and RARγ) and CYP26a1, an enzyme involved in 
RA metabolic inactivation, demonstrated that the KO for EGR1 affected the correct expression 
of these components during RA stimulation. In particular, it was interesting to note that CYP26a1 
showed a very smaller increased expression after 2 days of RA in KO than WT cells. The 
expression levels of CYP26A1 are crucial in regulating intracellular levels of RA and in 
determining cell fate (Osanai and Petkovich, 2005). Therefore, it can be hypothesized that the low 
levels of CYP26A1 in KO cells cause an insufficient degradation of retinoic acid, with subsequent 
accumulation up to cytotoxic levels that induce cell death. In addition, we demonstrated the up-
regulation of of RARγ in KO cells after 48 h of RA stimulation. The effect of this dysregulation 
is in line with data showing that RARγ appeared to control a differentiation-apoptosis switch in 
neuroblastoma cells (Ferrari et al.,1998). Considering that the BDNF system is induced by RA 
stimulation and is involved in differentiation and survival of neuronal cells, we also focused our 
attention on this system in RA-stimulated EGR1-KO cells. We observed that while the mRNA 
for BDNF increased in both WT and KO cells, the mRNA for NTRK2 increased less in KO cells 
than WT and, on the contrary, the mRNA level for NGFR was higher in KO than WT cells. NGFR 
signaling mediates different biologic effects compared to the NTRK receptors and is able to 
trigger programmed cell death (Casaccia-Bonnefil et al., 1996; Frade et al., 1996; Roux et al., 
1999; Dechant and Barde, 2002). This led us to speculate that the unbalance of the two receptor 
levels may contribute to the RA-induced cell death in EGR1-KO cells.  
Interestingly, in the present work, we identified an alternative splicing isoform for EGR1 never 
before described in literature. This isoform may be relevant for the EGR1 function in neuronal 
differentiation considering that its expression is regulated by RA and BDNF stimulation. It is 
worthy to note that the splicing event that produces this isoform belongs to a recently described 
splicing category that generates so-called “exitrons” (Marquez, 2015). Exitrons are defined as 
introns within protein-coding exons that, when retained, maintain the protein-coding potential of 
the transcript and contribute to transcriptome diversity in specific situations (Marquez, 2015; Park 
et al., 2018). The analysis of the putative protein encoded by the alternative splicing isoform 
showed that it maintains the nuclear localization signal and DNA binding domain. In fact, as 
shown by western blotting and immunolocalization analysis, the splicing isoform preferentially 
localized into the nucleus as the canonical EGR1 isoform. In addition, EGR1 lacked a region 
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belonging to N-terminal activation domain of EGR1 and corresponded to one of the two regions 
identified and described by Gashler and colleagues (1993) as important for its activity. This detail 
may explain the effect of the iper-expression of the EGR1 isoform that is unable to trigger the 
transcription of the two EGR1 target genes analysed in the present work (ARC and SIK1). This 
allows us to hypothesize that the alternative EGR1 isoform, when produced, may act as a negative 
competitor to the canonical EGR1 isoform as corroborated by the co-expression experiments. 
Although we obtained promising results, further investigations are needed to better characterize 
the expression pattern and the role of the alternative isoform in gene expression regulation. 
Concerning the lncRNAs regulated by BDNF, we focused our attention on LINC00473 and, in 
particular, on the splicing isoform LINC00473-202, which was the most differentially expressed 
under neurotrophin stimulation. In the vast majority of studies, LINC00473 has been shown to act 
as an oncogene in tumours where it is upregulated and likely affects cell proliferation, colony 
formation, cellular invasion, and epithelial-mesenchymal transition (EMT) (Chen et al., 2016; Shi 
et al.,2017; Chen et al., 2018; Zhu et al., 2018). In the present thesis, we showed different 
expression kinetics; in particular, the expression pattern under BDNF stimulation reported in the 
present thesis aligns with one of the first published papers that described LINC00473 as a primate-
specific IEG able to respond to the treatment with EP2 and EP4 agonists (Reitmair et al., 2011). 
In addition, we provided preliminary observations that the expression of the LINC00473 gene can 
be regulated by the transcription factor EGR1, providing an interesting functional relationship 
between these two BDNF-regulated genes. Reitmair and colleagues (2011) proposed LINC00473 
as a possible regulator of c-AMP-mediated gene expression since small interfering RNA-
mediated LINC00473 gene silencing experiments affected the expression of several cAMP-
responsive genes. Interestingly, a recent study demonstrated the expression of LINC00473 and 
other primate-specific lncRNAs in human iPSC-derived neuronal cells after activity (Pruunsild et 
al., 2017); in this paper, the authors argued that lineage-specific gain of lncRNAs might affect the 
synaptic activity-regulated gene program. lncRNAs can be translated and play a role in the 
evolution of new proteins. Our results demonstrated that the LINC00473-202 isoform has 
significant coding potential and that the putative protein is highly conserved in primate species. 
The actual production of a protein by the translation of this RNA remains to be demonstrated in 
the cell line and experimental paradigms used in this thesis. Recently, C6orf176 (LINC00473) 
was identify by mass spectrometry as one of the proteins differentially expressed after the 
treatment of HT-29 cells with the antitumoral peptide CIGB-552, providing evidence for the 
existence of this protein (Rodríguez-Ulloa et al., 2015). Our preliminary results on the effects of 
the deletion of the CDS region of LINC00473-202 on the transcript level changes of some IEGs 
after serum stimulation corroborated the hypothesis of a protein production and suggested that it 
can be involved in the regulation of gene expression regulation.  
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In conclusion, this thesis work provided the identification of coding and lncRNAs involved in 
human neuronal development and gave insights on their functional relationship and the molecular 
mechanism of action. 
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